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Endothelial dysfunction is the initiating step in atherosclerosis and leads to 
cardiovascular disease outcomes. This dysfunction can be mitigated by 
cardioprotective signaling molecules such as nitric oxide (NO) which can be 
upregulated in the presence of bioactive milk peptides. An investigation into the 
NO liberating capacity of select bioactive peptides was performed on cultures of 
Human Umbilical Vein Endothelial Cells (HUVECs) and two tripeptides (VPP and 
IPP) were found to liberate ~50% more NO. This finding drove a further 
investigation into whether endothelial cells grown on varying matrix stiffness 
would experience mechanical forces resulting in cellular responses more 
indicative of in vivo conditions. 
Polyacrylamide (PAC) gels of varying stiffness (2.5, 3, 10 and 30kPa) were 
prepared, and cell growth characteristics and inflammatory responses were 
measured over a nine day period. Findings showed that stiffer gels (10 and 30kPa) 
supported the growth of significantly higher numbers of HUVECs with smaller 
cell areas; however, gel stiffness did not induce a pro-inflammatory response in 
this cell line. Therefore, these results support PAC gels as useful in simulating a 





I would like to sincerely thank my supervisor, Dr. Holly Jones-Taggart, for 
the opportunity to work on this project. Her knowledge, expertise, and support 
are greatly appreciated through the research and writing process. I would also 
like to thank my advisory committee, Dr. Julia Green-Johnson and Dr. Janice L. 
Strap for their insights and willingness to help guide me towards success.  
I would also like to extend my gratitude towards Donna Smeeton and Joanne 
Free for their assistance in training me in the proper use of the Panoptiq imaging 
microscope. Sincere gratitude is also extended to Dr. Hendrick de Haan, 
Christopher Drossis and Michael Greenberg for their guidance in navigating the 
Image J software. Deep gratitude is also extended to Ryan Howson, in his help in 
designing coverslip racks that were pertinent towards my methodology.’ 
Heartfelt thanks are also extended to Michael Jeffrey and Dr. Sandra T. Clarke 
for your friendship and assistance in the completion of this project. 
Finally, I would like to deeply thank my family and friends for their help, 
patience and support through this journey, especially my husband, Roger Sawh, 





TABLE OF CONTENTS 
Abstract……...................................................................................................................... ii 
Acknowledgments .......................................................................................................... iii 
List of Tables ................................................................................................................... vii 
List of Figures ................................................................................................................ viii 
List of Appendices ........................................................................................................ xiv 
List of Abbreviations ..................................................................................................... xv 
1. Introduction ............................................................................................................... 1 
1.1. Cardiovascular Disease ....................................................................................... 1 
1.2. Inflammation and Atherosclerosis .......................................................... 3 
1.2. Promotion of a Dysfunctional Endothelium .................................................... 8 
1.2.1. Dysregulated  Blood Flow and Arterial Stiffening ............................. 10 
1.2.1.1. Hypertension ............................................................................ 10 
1.2.1.2. Turbulent Blood Flow .............................................................. 12 
1.2.2. Oxidized Low-Density Lipoprotein and eNOS Activity.................... 13 
1.2.3 Hyperinsulinemia and Insulin Resistance............................................ 14 
1.2.4. Hyperglycemia ......................................................................................... 16 
1.3. Immunological Biomarkers .............................................................................. 17 
1.3.1. Interleukin-6 (IL-6) ................................................................................... 17 
1.3.2. Monocyte Chemoattractant Protein -1 (MCP-1) .................................. 18 
1.3.3. Soluble Intercellular Adhesion Molecule-1 (sICAM-1) ...................... 19 
1.4. Nitric Oxide as a Cardioprotective Molecule ................................................ 20 
1.5. Dairy Consumption and Cardiovascular Disease ......................................... 21 
1.5.1. Cardioprotection by Bioactive Peptides ............................................... 23 
1.5.1.1. Antihypertensive Properties of Bioactive Milk Peptides ... 23 
1.5.1.2. Immunomodulatory Effects of Bioactive Milk Peptides .... 25 
1.5.1.3. Bioactive Peptide Effect on Arterial Stiffness ....................... 26 
v 
 
1.6. Development of Physiologically Relevant Models to Study the 
Endothelium ....................................................................................................... 27 
1.7. Objectives ............................................................................................................ 31 
1.7.1. Characterization of Nitric Oxide Liberation by  
Bioactive Peptides in an Endothelial Cell Culture Model ................. 31 
1.7.2. Characterization of Behavioural Response of  
HUVECs to Growth on Stiffened Extracellular Matrices .................. 32 
2. Methodology ........................................................................................................... 33 
2.1. Cell Culture ......................................................................................................... 33 
2.2. Synthesized Peptides ......................................................................................... 34 
2.3. Nitric Oxide Liberation Assay ......................................................................... 37 
2.4. Stiffness Controlled Extracellular Matrix ....................................................... 38 
2.5. Cell Population Imaging ................................................................................... 43 
2.6. Cell Growth Metrics .......................................................................................... 43 
2.7. Cytokine Quantification .................................................................................... 44 
2.8. Statistical Analysis ............................................................................................. 45 
3. Results 46 
3.1. Nitric Oxide Liberating Abilities of Bioactive Peptides. .............................. 46 
3.2. Characterization of HUVECs Grown on Stiffened PAC Matrices  
– Growth Metrics................................................................................................ 48 
3.2.1. Cell Growth Metrics ................................................................................ 48 
3.2.2. Cell Count ................................................................................................. 48 
3.2.3. Cell Area .................................................................................................... 51 
3.3. Characterization of HUVECs Grown on Stiffened PAC Matrices  
– Release of Cytokines ....................................................................................... 54 
3.3.1. IL-6 ............................................................................................................. 54 
3.3.2. MCP-1 ........................................................................................................ 56 
3.3.3. sICAM-1 .................................................................................................... 56 
4. Discussion ................................................................................................................ 61 
4.1. Cell Culture ......................................................................................................... 61 
vi 
 
4.2. Nitric Oxide Liberation by Bioactive Peptides .............................................. 62 
4.3. Characterization of HUVECs Grown on Stiffened PAC Matrices  
– Growth Metrics................................................................................................ 65 
4.4. Characterization of HUVECs Grown on Stiffened PAC Matrices  
– Release of Cytokines ....................................................................................... 69 
4.5. Conclusions and Future Directions ................................................................. 74 
5. Works Cited ............................................................................................................. 76 
I. Appendix A ............................................................................................................. 88 
II. Appendix B .............................................................................................................. 91 




LIST OF TABLES 
Table 1. Synthesized peptide sequence, molecular weight, and reference 
source of β-casein derived peptides from fermentation by 
Lactobacillus helvicus 
  
Table 2. Volume of Acrylamide and bis-Acrylamide used to produced 
1000μL of stiffness controlled PAC gel (Galie et al., 2015) 
  
Table 3. Fold change in HUVEC cell count between day 3-6 and day 6-9. 
Cells imaged using Panoptiq digital imaging (ViewsIQ, Richmond, 
BC) and counted using Image J (NIH, MD, USA) 
  
Table 4. Mean cell area of fixed and stained HUVECs grown on various 
stiffened extracellular matrices. Cells imaged using Panoptiq 
digital imaging (ViewsIQ, Richmond, BC) and counted using 
Image J (NIH, MD, USA). Statistical Analysis was done using a 
Mann-Whitney-U test (p<0.05) 
  
Table 5.  Fold change in total area occupied by HUVECs between day 3-6 
and day 6-9. Cells imaged using Panoptiq digital imaging 






LIST OF FIGURES 
Figure 1. Endothelial expression of adhesion molecules directing the 
migration of monocytes towards innermost muscle layer, 
leading to the differentiation into macrophages, and 
eventually foam cells from the uptake of oxLDLs. T-cell 
mediated immunity can also be observed here, where the 
endothelial layer expresses MHC molecules signaling the 
infiltration of foreign bodies. 
 
Adaptation by permission from Macmillan Publishers Ltd: 
[Nature] (Libby, P., Ridker, P., Hansson, G. 2011. Progress and 
challenges in translating the biology of atherosclerosis. 
Nature. 473.) Copyright 2011. (2011) 
 
Figure 2. Foam cell aggregation forming the atheromatous core. 
Smooth muscle cells are also migrating to the luminal surface 
forming the fibrous cap of the fatty streak.   
 
Adaptation by p Adaptation by permission from Macmillan 
Publishers Ltd: [Nature] (Libby, P., Ridker, P., Hansson, G. 
2011. Progress and challenges in translating the biology of 
atherosclerosis. Nature. 473.) Copyright 2011. (2011) 
 
Figure 3.  Schematic of polyacrylamide overlaid on top of an activated 
coverslip, further treated with collagen to allow for cell 
attachment and growth. 
 
Figure 4. HUVEC were cultured with 10μM of each peptide in 
MCDB131 enriched media for 1 hour (n=6). Data shown are 
the relative nitric oxide amounts produced by each cell culture 
as a percentage of the untreated. Where the horizontal line at 
100 represents the average nitric oxide produced while 
untreated. Statistical analysis was performed using Mann-









Figure 5. Comparison of cell count between stiffnesses across days; 
HUVEC cell count after 3, 6 and 9 days of incubation on 
varying PAC gel stiffness; with enriched MCBD 131 media at 
37oC with 5% CO2 (n=3-4). Cells imaged using Panoptiq 
digital imaging (ViewsIQ, Richmond, BC) and counted using 
Image J (NIH, MD, USA). ‘a’ denotes no statistical significance 
while ‘b’ represents statistically significant cell counts, as 
determined using a one-way ANOVA (p<0.05) and Tukey’s 
multiple comparison tests. Cell counts found at day 6 at 
stiffness 30kPa was found to be statistically higher when 
compared to cell counts of other stiffness at the same time 
point. 
 
Figure 6. Comparison of the total area occupied by HUVECs after 3, 6 
and 9 days of incubation on varying PAC gel stiffness; with 
enriched MCBD131 media at 37oC with 5% CO2 (n=3-4). Cells 
imaged using Panoptiq digital imaging (ViewsIQ, Richmond, 
BC) and measured using Image J (NIH, MD, USA). Statistical 
analysis was done using a non-parametric Mann-Whitney U 
test comparing stiffness at a given time point to 2.5kPa 
(Control) of the same time point (p<0.05). 
 
Figure 7. IL-6 production by HUVEC culture grown on stiffened 
extracellular matrices for 3, 6 and 9 days (n=5). Data 
represents standardized IL-6 production by average cell count 
for related treatment groups. Statistical analysis was done 
using a one way ANOVA comparing stiffness at a given time 
point to 2.5kPa (Control) of the same time point (p<0.05). 
 
Figure 8. MCP-1 production by HUVEC culture grown on stiffened 
extracellular matrices for 3, 6 and 9 days (n=5). Data 
represents standardized MCP-1 production by average cell 
count for related treatment groups. . Statistical analysis was 
done using a one way ANOVA comparing stiffness at a given 
time point to 2.5kPa (Control) of the same time point (p<0.05). 
 
Figure 9. Soluble ICAM-1 production by HUVEC culture grown on 
stiffened extracellular matrices for 3, 6 and 9 days (n=3). Data 
represents standardized sICAM-1 production by average cell 
count for related treatment groups. Statistical analysis was 
done using a one way ANOVA comparing stiffness at a given 






HUVEC culture grown on collagen coated cover slips 3 days 
after initial seeding (passage=2,3). Fixed with 2% 
paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 




HUVEC culture grown on collagen coated cover slips 6 days 
after initial seeding (passage=2,3). Fixed with 2% 
paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 




HUVEC culture grown on collagen coated cover slips 9 days 
after initial seeding (passage=2,3). Fixed with 2% 
paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 




HUVEC culture grown on 2.5kPa polyacrylamide gel overlaid 
on cover slips, 3 days after initial seeding (passage=2,3). Fixed 
with 2% paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 












HUVEC culture grown on 2.5kPa polyacrylamide gel overlaid 
on cover slips, 6 days after initial seeding (passage=2,3). Fixed 
with 2% paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 




HUVEC culture grown on 2.5kPa polyacrylamide gel overlaid 
on cover slips, 9 days after initial seeding (passage=2,3). Fixed 
with 2% paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 




HUVEC culture grown on 3kPa polyacrylamide gel overlaid 
on cover slips, 3 days after initial seeding (passage=2,3). Fixed 
with 2% paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 




HUVEC culture grown on 3kPa polyacrylamide gel overlaid 
on cover slips, 6 days after initial seeding (passage=2,3). Fixed 
with 2% paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 












HUVEC culture grown on 3kPa polyacrylamide gel overlaid 
on cover slips, 9 days after initial seeding (passage=2,3). Fixed 
with 2% paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 




HUVEC culture grown on 10kPa polyacrylamide gel overlaid 
on cover slips, 3 days after initial seeding (passage=2,3). Fixed 
with 2% paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 




HUVEC culture grown on 10kPa polyacrylamide gel overlaid 
on cover slips, 6 days after initial seeding (passage=2,3). Fixed 
with 2% paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 




HUVEC culture grown on 10kPa polyacrylamide gel overlaid 
on cover slips, 9 days after initial seeding (passage=2,3). Fixed 
with 2% paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 












HUVEC culture grown on 30kPa polyacrylamide gel overlaid 
on cover slips, 3 days after initial seeding (passage=2,3). Fixed 
with 2% paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 




HUVEC culture grown on 30kPa polyacrylamide gel overlaid 
on cover slips, 6 days after initial seeding (passage=2,3). Fixed 
with 2% paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 




HUVEC culture grown on 30kPa polyacrylamide gel overlaid 
on cover slips, 9 days after initial seeding (passage=2,3). Fixed 
with 2% paraformaldehyde and stained with safranin. Images 
obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area 
measurements. The image above was loaded into ImageScope 
(Leica Biosystems) and a sample of the image was captured at 






LIST OF APPENDICES 
Appendix A : Copyright permission for use of previously published figures 
Appendix B : Structure and properties of bioactive peptides 
  




LIST OF ABBREVIATIONS 
ACE - Angiotensin Converting Enzyme 
AFM - Atomic Force Microscopy 
AGE –Advanced Glycation End Products 
Ang-I - Angiotensin I 
Ang-II - Angiotensin II 
BAEC - Bovine Aortic Endothelial Cell 
CDK – Cyclin-Dependent Kinase 
CVD - Cardiovascular Disease 
DMEM - Dulbecco’s Modified Eagle Medium 
ECGS - Endothelial Cells Growth Supplement 
ECM - Extracellular Matrix 
EGF - Endothelial Growth Factor 
ELISA - Enzyme-Linked Immunosorbent Assay 
eNOS - Endothelial Nitric Oxide Synthase 
ET-1 - Endothelin- 1 
FCS - Fetal Calf Serum 
G-LISA - Small G-protein Activation Assay 
HAEC - Human Aortic Endothelial Cells                               
HRP - Horseradish Peroxidase 
HUVEC - Human Umbilical Vein Endothelial Cell 
ICAM-1 - Intercellular Adhesion Molecule- 1 
IGF-1 - Insulin Growth Factor- 1 
IL-1 – Interleukin-1  
IL-4 – Interleukin- 4 
IL-6 - Interleukin- 6 
kPa - Kilo Pascal 
xvi 
 
LAB - Lactic Acid Bacteria 
LFA-1 - Lymphocyte Function-Associated Antigen- 1 
LPL - Lipoprotein Lipase  
LPS - Lipopolysaccharide 
mBMEC - Mouse Brain Microvascular Endothelial Cells  
MCP-1 - Monocyte Chemoattractant Protein- 1 
M-CSF - Monocyte Colony Stimulating Factor 
MI – Myocardial Infarction 
NO - Nitric Oxide 
NOX2 - NAPDH oxidase 
oxLDL - Oxidized Low-Density Lipoprotein 
PAC - Polyacrylamide  
PBS – Phosphate buffered saline 
RAAS - Renin-Angiotensin-Aldosterone System 
ROCK - RhoA kinase  
sICAM-1 - Soluble Intercellular Adhesion Molecule- 1  
SNP - Short Nucleotide Polymorphism 
TdT - Terminal Deoxynucleotidyl Transferase  
TEER - Transendothelial Electrical Resistance 
TMB - 3,3’,5,5’-tetramethylbenzidine  
TNF-α - Tumor Necrosis Factor Alpha 
TUNEL - TdT dUTP Nick-End Labeling 




1.1. Cardiovascular Disease 
Cardiovascular Disease (CVD) is a term that refers to all diseases of the 
circulatory system, although the leading manifestations are heart disease and 
stroke (Public Health Agency of Canada, 2016). The two most prominent causes of 
CVD share the same underlying characteristic, whereby they are all initiated by 
some form of vascular blockage. This blockage is most commonly due to 
atherosclerosis, a gradual process that causes plaque to build up inside the arteries, 
causing the narrowing, obstructing, and occluding of the vasculature (National 
Heart, Lung and Blood Institute, 2016).  Globally, the mortality rate of CVD is 17.7 
million people, accounting for 31% of deaths (WHO, 2017).  Statistics Canada 
estimated that approximately 50,000 Canadians died due to diseases of the heart 
in 2013, accounting for 20% of all deaths in Canada. Additionally, 1 in 12 Canadian 
adults lives with diagnosed CVD. The economic burden as a result of CVD is 
estimated to be $21.2 billion annually (Tarride et al., 2009).  
Although there are many risk factors that can contribute to CVD, these risks 
can generally be separated into two categories. The first category consists of 
modifiable risk behaviours, such as habits and/or addictions (i.e. smoking and 
sedentary lifestyle).  The second category consists of underlying conditions that 
are able to promote the development of atherosclerosis, such as hypertension and 
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inflammation. Atherosclerosis can be exacerbated by inflammation and triggered 
by hypertension. Hypertension, as defined by the Public Health Agency of 
Canada, is an increase in systolic and diastolic blood pressure. Increased blood 
pressure disrupts the pattern of blood flow within the vasculature and initiates 
damage (Cybulsky and Marsden, 2014).  The lining of the vasculature, known as 
the endothelium, is composed of specialized endothelial cells. These cells are 
subjected to low-velocity blood flow in normotensive individuals due to the fact 
that laminar blood flow allows the blood to move at its highest velocity at the 
centre of the vessel, and thus the outer endothelial layers experience minimal 
amounts of shear stress (Stonebridge and Brophy, 1991). In hypertensive 
individuals, blood moves and travels at differing magnitudes and velocities; this 
is referred to as turbulent flow and it causes an increase in endothelial cell stress 
and turnover (Cybulsky and Marsden, 2014).  As the rate of cell renewal becomes 
lower than the rate of apoptosis and the number of cells decreases within the 
endothelial layer, there is a loss of cell connections along the endothelial lining and 
the normal function of the endothelial barrier deteriorates (Tricot et al., 2000).  Once 
the endothelial barrier becomes dysfunctional, inflammatory responses to the 
infiltration of the barrier further promote the pathological progression of 
atherosclerosis.   Acute and chronic CVD from the development of blockages in 
the vasculature is a progressive, insidious disease that begins with the loss of the 
normal function of the endothelium. 
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1.2.  Inflammation and Atherosclerosis  
A common underlying factor of CVD is a vascular blockage that stops the 
flow of blood to various organs; the underlying cause of this vascular narrowing 
and blockage is due to a process termed atherosclerosis. Atherosclerosis 
progresses slowly and eventually manifests as a fatty streak that either occludes 
the arterial lumen or it ruptures, releasing stored material from the fatty streak 
into the artery causing a thromboembolism (Libby, 2006). A thromboembolism can 
rupture and release an embolism that will travel in the vasculature until an 
occlusion occurs, cutting off blood delivery of oxygen and nutrients to all 
downstream tissues.  This will can cause myocardial infarctions (MI or heart 
attack) or stroke if the embolism reaches the brain.  
Atherosclerosis, once believed to be caused solely by unmanaged 
cholesterol levels, has now been classified as an inflammatory disease, where the 
body’s natural reaction to infection and cell damage turn against the body’s 
endothelial cells (Libby, 2006). This inflammatory response is initiated by a change 
in the structure of the endothelium lining the arteries. Under normal conditions, 
monocytes are not able to attach to endothelial cells; however, a damaged or 
dysfunctional endothelium allows and perpetuates an immune response (Figure 
1, Libby et al., 2011). The change in morphology of the endothelial lining could be 
brought on by the factors of high oxLDL, impaired insulin and glucose 
metabolism, dysregulated blood flow and stiffening of the arteries as described 
4 
 
above. Each can stimulate the endothelial cells to release cytokines that activate an 
immune response. Inflammatory cytokines, such as intercellular adhesion 
molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) as well as 
monocyte recruitment cytokines, such as macrophage colony stimulating factor 
(M-CSF) have been reported to be released by endothelial cells under stress (Libby 
et al., 2011). M-CSF signals for the increased presence of monocytes while ICAM-1 
and VCAM-1, as adhesion molecules, promote binding of these monocytes to the 
endothelial layer (Libby et al., 2011). Once bound, these monocytes are able to 
migrate beneath the endothelial layer to the smooth muscle layer. This migration 
is mediated by a chemoattractant gradient of MCP-1 released by the endothelium 
(Libby et al., 2011).  
Once under the endothelial layer, the monocytes differentiate into 
macrophages; these macrophages express scavenger receptors which allow them 
to attract and ingest LDLs. The phagocytosis of LDLs increases the volume of the 
monocyte cytoplasm, eventually leading to differentiation into foam cells (Libby, 
2002). These foam cells then express E-cadherin, a signaling molecule that attracts 
other foam cells for further aggregation, eventually leading to the formation of the 
atheromatous core – the center of the atherosclerotic plaque characterized by the 
collection of cellular debris and oxLDL (Bobryshev, 2006). The foam cells and 
endothelial cells are then able to secrete signaling factors for smooth muscle cells 
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to replicate and migrate to the apical surface of the endothelial layer forming the 





Figure 1. Endothelial expression of adhesion molecules directing the migration of 
monocytes towards innermost muscle layer, leading to the 
differentiation into macrophages, and eventually foam cells from the 
uptake of oxLDLs. T-cell mediated immunity can also be observed here, 
where the endothelial layer expresses MHC molecules signaling the 
infiltration of foreign bodies. 
Adaptation by permission from Macmillan Publishers Ltd: [Nature] 
(Libby, P., Ridker, P., Hansson, G. 2011. Progress and challenges in 






Figure 2. Foam cell aggregation forming the atheromatous core. Smooth muscle 
cells are also migrating to the luminal surface forming the fibrous cap of 
the fatty streak.   
Adaptation by permission from Macmillan Publishers Ltd: [Nature] 
(Libby, P., Ridker, P., Hansson, G. 2011. Progress and challenges in 





This atherosclerotic plaque is able to progress outwards, weakening the 
outer vessel wall;  however, it may begin to grow inwards towards the lumen of 
the blood vessel, effectively narrowing the artery and decreasing the flow of blood.  
Eventually, this will lead to total occlusion of the artery or it may reach the elastic 
limits of the fibrous cap causing it to rupture and release the atheromatous core. 
The thromboembolism then travels downstream until a total blockage occurs, 
thereby causing an ischemic event (Libby, 2002). 
1.2. Promotion of a Dysfunctional Endothelium 
A healthy endothelium creates a barrier between the lumen of the blood vessel 
and the smooth muscle cells. It is a semipermeable membrane that mediates the 
diffusion of extracellular material into the smooth muscle layer of the vasculature. 
The endothelial lining is maintained by sufficient cell to cell communication 
allowing the cells to form junctional complexes with neighbouring endothelial 
cells (Bazzoni and Dejana, 2004). Through this efficient communication network 
and cell-cell contact, the endothelial lining is able to maintain barrier function as 
well as a homeostatic balance with the smooth muscle layer that regulates 
vasoconstriction and vasodilation. A key player in the homeostatic regulation of 
vasomotor activity is the signaling molecule nitric oxide (NO), which is a potent 
vasodilator produced and released by healthy endothelial cells in intricate 
responses to blood pressure changes (Ignarro et al., 1987).  NO then diffuses into 
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the smooth muscle layer, signaling smooth muscle cell relaxation allowing for 
vasodilation. 
Endothelial dysfunction is characterized by an increased permeability to blood 
components such as leukocytes, oxidized low-density lipids (oxLDL), and 
aggregated platelets (Davignon and Ganz, 2004), as well as a loss of NO generating 
capacity (Föstermann and Sessa, 2012). The loss of cell-cell connections, such as 
gap junctional complexes, causes the endothelial layer to lose barrier function and 
become susceptible to infiltration by these blood components.  This progressively 
causes the endothelial cells within the layer to begin distress signaling to the 
immune system, resulting in further accumulation of leukocytes and platelets 
locally (Jongstra-Bilen et al., 2006). Additionally, monocytes are able to easily 
migrate under the endothelial layer due to these gaps between endothelial cells, 
driving inflammatory response, and endothelial dysfunction, further (Rubin and 
Damjanov, 1989). 
The process of endothelial dysfunction is complex and driven by factors 
outside of the endothelial cell to cause an imbalance of the homeostatic 
mechanisms required to maintain a functioning barrier. The factors contributing 
to the decline in barrier function include dysregulated blood flow - both 
hypertension (Hsieh et al., 2014) and turbulent flow (Cybulsky and Marsden, 
2014), age and/or pressure related arterial stiffening (Baeyens and Shwartz, 2015), 
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oxLDL infiltration, insulin and glucose dysregulation (Rask-Marsden and King, 
2007) and plaque formation (Libby, 2006). 
1.2.1. Dysregulated  Blood Flow and Arterial Stiffening 
Disturbances in blood flow dynamics can be characterized in one of two 
ways; an increase in overall blood pressure – typically referred to as hypertension 
or as turbulent flow – which is typically found at arterial branch points and occurs 
due to the divergence of blood flow. This dysregulated blood flow, if sustained, 
will eventually cause the pathology of arterial stiffening. Arterial stiffening is 
considered to be an inevitable consequence of age, however much evidence has 
been brought forward to implicate unmanaged hypertension as an early cause of 
arterial stiffening. This is mostly due to the constant cyclical shear stress endured 
by the arteries over time that causes changes in the extracellular matrix (ECM) 
such as increased collagen deposits as well as changes in the smooth muscle layer 
that alter its ability to stretch  (Cecelja and Chowienczyk, 2012). 
1.2.1.1. Hypertension 
Blood vessels respond to differing hemodynamic forces. In areas where 
high pressure is present, the blood vessels need to adapt to maintain homeostasis 
by reacting to changes in shear stress and hydrostatic pressure. Shear stress is the 
tangential friction force acting on the vessel wall, whereas hydrostatic pressure is 
both the perpendicular force acting on the vascular wall and cyclic strain on the 
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stretch within the vessel wall (Hsieh et al., 2014). In hypertensive individuals, 
arteries constantly undergo structural changes to adapt to the increased pressure. 
These structural changes are hypertrophic and typically involve an overall change 
in the smooth muscle layer and lumen ratios. Hypertrophic remodeling is a 
response to this change in pressure involving thickening of the muscle layer 
resulting in a reduction in lumen diameter (Intengan and Schiffrin, 2000). The 
decrease in the diameter of the lumen causes an increase in pressures on the 
endothelial layer. This increased pressure from the pulsating blood is transferred 
from the endothelium to the elastin and collagen fibers of the muscle layer of the 
arteries.  This causes changes to the ECM – an increase in collagen production, the 
breakdown of elastin – and infiltration of smooth muscle cells leading to overall 
stiffening of the artery (Díez, 2007).  If the increased pressure is sustained and the 
hypertrophic remodeling is not reversed, arterial stiffening will result, causing loss 
of the elastic recoil abilities of the vasculature (Cecelja and Chowienczyk, 2012) 
and a rigid ECM for the endothelium.  This rigidity of the surface on which the 
endothelial cells attach compromises their ability to maintain cell-cell junctional 
connections for the optimal barrier function of the endothelium.  In areas of 
increased stiffness, the junctional complexes that normally allow for healthy cell 
to cell communication disappear as endothelial cells begin to be pulled along the 
stiffened muscular layer (Krishnan et al., 2011). In an experiment using human 
umbilical vein endothelial cells (HUVECs) cultured on polyacrylamide gel 
substrates, Krishnan et al. (2011) found that monolayer cultures grown on softer, 
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more compliant substrates were better able to withstand force in the presence of a 
permeability stimuli (thrombin), and the monolayer was observed to react in 
unison. In contrast, monolayers on stiffer polyacrylamide substrates could not 
withstand the same force, and gaps were generated between neighbouring 
endothelial cells (Krishnan et al., 2011). 
1.2.1.2. Turbulent Blood Flow 
Turbulent flow is typically present at the inner curvature or bifurcations 
of the arteries, however, laminar blood flow is normally regained a short distance 
away from the arterial branch point. Endothelial cells at these branch points 
display different morphologies and gene expression patterns than their 
counterparts under laminar flow, and it is at these locations where atherosclerotic 
lesions are most likely to initiate (Cybulsky and Marsden, 2014).  This is likely due 
to factors such as chronic low-grade inflammation, increased cell proliferation, or 
cytoskeletal reorganization that may contribute to a dysfunctional endothelium.  
Under turbulent flow, endothelial cells express a chronic low-grade 
inflammatory response, more specifically up-regulation of interleukin- 1 (IL-1), 
interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) (Jongstra-
Bilen et al., 2006). This chronic low-grade inflammation does not normally lead to 
atherosclerosis; however, Davies et al., (1986) demonstrated that cell turnover was 
significantly higher in a cell-based model using bovine aortic endothelial cells 
(BAECs). BAECs were placed under turbulent flow in vitro and compared to 
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BAECs under high shear stress experiencing laminar flow. The authors found that 
endothelial cell turnover was increased in cells undergoing low shear stress with 
the turbulent flow when compared to endothelial cells experiencing high shear 
stress in laminar flow. Therefore, it was suggested that this chronic low-grade 
immune response, coupled with high cell turnover could combine with other CVD 
risk factors to promote a dysfunctional endothelium and allow for the 
development of atherosclerotic plaques. 
1.2.2.  Oxidized Low-Density Lipoprotein and eNOS Activity 
In atherosclerosis the fatty streak contains both low-density lipoproteins 
(LDLs) as well as their oxidized counterparts (oxLDL); however, the level of LDL 
is lower when compared to oxLDL (Steinbrecher et al., 1984). This observation lead 
researchers to hypothesize that LDLs undergo endothelial cell mediated 
modifications. It was found that this modification was through oxidation of lipids 
by reactive oxygen species, such as superoxide and hydrogen peroxide (Morel et 
al., 1983). Beyond this, oxLDLs were assumed to only contribute to the formation 
of foam cells present in the necrotic plaque in late-stage atherosclerosis; however, 
recent studies have demonstrated that oxLDLs also affect endothelial homeostasis 
through disruption of the regulation of endothelial nitric oxide synthase (eNOS) 
activity (reviewed by Levitan and Shenty, 2011 ). eNOS is the endothelial isoform 
of the enzyme responsible for catalyzing the conversion of the amino acid L-
arginine to L-citrulline, which liberates NO (Cockcroft, 2005).  eNOS activity has 
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been demonstrated to be directly regulated by the integral membrane protein of 
the phospholipid bilayer caveolae (Blair et al., 1999). Caveolae – Latin for “little 
caves” – are specialized, cholesterol-rich, invaginations of the plasma membrane 
and are found in many cell types but are most prevalent in endothelial cells and 
adipocytes (Govers and Rabelink, 2001). Caveolin-1 is able to bind to eNOS via its 
scaffolding domain and the interaction maintains eNOS in an inactive state when 
cytosolic calcium levels are low (Govers and Rabelink, 2001). When cytosolic 
calcium levels become elevated, eNOS dissociates from caveolin to become 
phosphorylated – this process is promoted by the calcium-calmodulin complex 
(Blair et al., 1999). In experiments using cultured endothelial cells, it was shown 
that oxLDLs are able to impede the association of eNOS and caveolae by altering 
the composition of caveolae by depleting them of cholesterol (reviewed by Shaul, 
2003). In this way, oxLDLs contribute to endothelial dysfunction through the 
inhibition of eNOs activity in endothelial cells. 
1.2.3 Hyperinsulinemia and Insulin Resistance 
A healthy endothelial layer is able to regulate the passage of insulin into 
tissues along with glucose in order to feed the cellular process of glycolysis 
occurring within the tissues (King et al., 2016). However, the effect of 
hyperinsulinemia and insulin resistant states are positively correlated with arterial 
stiffness across all age groups (Zieman et al., 2005). This is due to insulin signaling 
both through the insulin receptor and other pathways to stimulate gene expression 
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profiles that drive cell proliferation and specialized cell functions. In insulin 
resistance, these pathways are no longer responsive to insulin, leading to loss of 
normal endothelial cell responses.  However, hyperinsulinemia drives other 
pathways apart from the insulin receptor signaling that continue to have 
proliferative effects on the vasculature. 
Insulin’s role in endothelial cell function was demonstrated through 
multiple reports of its upregulation of NO production. Kuboki et al., (2000) showed 
eNOS mRNA and expression in BAECs increased 2-fold after 12 hours using 
physiological concentrations of insulin. Further, Kuboki et al., (2000) exposed 
vascular tissue isolated from Zucker lean and fatty insulin-resistant rats to 
100nmol/L of insulin. Insulin was found to increase eNOS mRNA expression by 
50% in the lean rat model but had no effect on the insulin-resistant rats. The 
activity of insulin is now known to be mediated through cellular 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling in healthy 
endothelium; Montagnani et al., (2002) used a HUVEC model to directly link PI3 
kinase signaling to eNOS expression.  Since insulin resistant states are 
characterized by inhibition of PI3 kinase signaling (due to loss of insulin receptor 
signaling) both endothelial eNOs activity and NO production are impacted, 
contributing to endothelial dysfunction.   
Insulin has stimulatory properties mediated through other pathways that 
directly affect endothelial function.  High insulin levels lead to upregulation of 
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endothelin-1 (ET-1), a potent vasoconstrictor. Nagai et al., (2003) demonstrated this 
by using human aortic endothelial cells (HAECs) treated with insulin and anti-
insulin-like growth factor- 1 (IGF-1) receptor antibody to show that concentrations 
of insulin 100μU/mL or higher significantly stimulated ET-1 production and this 
was inhibited in the presence of anti-IGF-1 receptor antibody.  This study was 
extended to examine the effect of insulin on growth rates of vascular smooth 
muscle cells; it was found that culture growth was increased with greater than 
330μU/mL of insulin.  This study demonstrated that high insulin levels could 
increase vasoconstriction of the blood vessel through upregulation of ET-1 as well 
as promote vessel stiffening through increased proliferation of vascular smooth 
muscle cells.  
Both of these conditions of high blood insulin levels and insulin resistance 
therefore further exacerbate and promote a dysfunctional endothelium. 
1.2.4. Hyperglycemia 
Hyperglycemia is characterized by an excess of circulating glucose; this 
glucose could spontaneously and irreversibly react with lysine residues on 
proteins – such as collagen – forming advanced glycation end products (AGEs) 
(Verzijl et al., 2000). The formation of AGEs then alters the binding properties of 
collagen, therefore increasing arterial stiffness (Zieman et al., 2005). AGEs have 
also been shown to bind to their receptor, receptor for advanced glycation end 
products (RAGE), which is able to elicit downstream signaling cascades leading to 
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the reduction of NO  and eNOS expression (Ren et al., 2017). RAGE downstream 
signaling can also activate NF-B to stimulate a pro-inflammatory cytokine 
response, therefore further promoting a dysfunctional endothelium (Ren et al., 
2017). 
1.3. Immunological Biomarkers 
Atherosclerosis is initiated through the dysfunction of the endothelial lining 
which in turn causes the release of cytokines and overexpression of adhesion 
molecules, as described. In relation to this project, the endothelial cell expression 
levels of IL-6, MCP-1 and soluble ICAM-1 (sICAM-1) were investigated in relation 
to external mechanical stress induced by culturing them on increasing matrix 
stiffness, mimicking vascular stiffening.  
1.3.1. Interleukin-6 (IL-6) 
IL-6 is a cytokine released by various cells, such as T-cells, B cells, 
endothelial cells and fibroblasts, and plays a crucial role in the recruitment of 
leukocytes to sites of inflammation. As demonstrated by Romano et al., (1997), 
mice deficient in IL-6 production showed defective recruitment of leukocytes to 
subcutaneous regions injected with an irritant that should otherwise induce an 
immune reaction. This effect was reversed by the local administration of IL-6. 
Analysis of the promoter region of the IL-6 gene revealed the presence of an NF-
B transcription factor binding site that would promote gene expression through 
inflammatory signaling (Libermann and Baltimar, 1990). Activation of NF-B 
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occurs in response to a number of known inflammatory stimuli, such as 
lipopolysaccharide (LPS) and tumor necrosis factor α (TNF- α). Kobayashi et al., 
(2003) demonstrated that NF-B activation led to the upregulation and secretion 
of IL-6 in a culture of HUVECs that were stretched by a silicone membrane on 
which they had been grown.    
1.3.2. Monocyte Chemoattractant Protein -1 (MCP-1) 
MCP-1 is a potent chemotactic factor aiding in monocyte migration beneath 
the endothelial layer (Deshamne et al., 2009). MCP-1 exposure has also been 
associated with a reduction of gap junctional complexes within the endothelium, 
promoting a dysfunctional state. Stamatovic et al., (2003) investigated the 
transendothelial electrical resistance (TEER) as a measure of tight junction 
integrity through electrical resistance. A decrease in electrical resistance indicates 
a shortened electrical pathway and thus loss of gap junction complexes. In this 
model, mouse brain microvascular endothelial cells (mBMEC) were cultured in 
the presence or absence of MCP-1 protein.  Resistance was observed to decline in 
a time-dependent manner when mBMECs were incubated with 100nM of MCP-1 
for 60 minutes (declined from 118 cm2 to 19 cm2).  Resistance was also found 
to decrease in a dose-dependent manner where the lowest concentration of     
MCP-1 to decrease endothelial resistance was 20nM, thus suggesting that even low 




1.3.3. Soluble Intercellular Adhesion Molecule-1 (sICAM-1) 
Soluble ICAM-1 belongs to immunoglobulin superfamily but differs from 
its parent molecule ICAM-1 in that it represents the cleaved, circulating 
derivation.sICAM-1 has been demonstrated to promote angiogenesis through 
stimulating HUVEC cell migration and tube formation in vitro (Gho et al., 1999).It 
has also been reported that sICAM-1 can induce tumor growth in vitro in human 
prostate adenocarcinoma (PC3), human fibrosarcoma (HT1080), and immortalized 
human mammary epithelial cells (HMECs) (Gho et al., 2001).   The parent molecule 
ICAM-1 interacts with lymphocyte function-associated antigen (LFA-1) in order 
to allow for leukocyte transmigration to the intimal surface. In a study by Meyer 
et al., (1995), it was found that sICAM-1 is able to inhibit the interaction of LFA and 
ICAM-1 at an IC50 level of 20-40uM, giving rise to its anti-inflammatory properties. 
However, sICAM-1 can also signal for additional lymphocytes to congregate 
towards the area of expression – displaying its pro-inflammatory properties (Chae, 
C. et al., 2001). sICAM-1 was chosen as a biomarker since in studies plasma levels 
of sICAM-1 have been shown to be indicative of atherosclerotic events. In a study 
by Hwang et al., (1997) blood samples were taken from individuals presenting risk 
factors for heart disease e.g. hypertension, smoking, obesity etc. sICAM-1 levels 
were seen to be elevated in this group when compared to levels in the control 
group. This elevation was observed 5 years prior to subjects’ first myocardial 
infarction (MI). These findings were further supported by Ridker et al., (1998) 
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where sICAM-1 levels were seen to be elevated 9 years earlier in apparently 
healthy individuals who eventually experienced an MI. 
1.4. Nitric Oxide as a Cardioprotective Molecule 
Vasomotor activity is mediated by extrinsic factors such as hormones and 
nervous signaling, but the most potent intrinsic vasodilatory activity is controlled 
through NO release by endothelial cells (Govers and Rabelink, 2001). In the past 
there have been conflicting viewpoints regarding NO effects on the vasculature 
during ischemic events. Earlier researchers concluded that NO is detrimental to 
the vasculature due to the production of reactive oxygen species such as 
superoxide, peroxynitrite and hydrogen peroxide (Mori et al., 1998, Wang et al., 
1999, Flögel et al., 1999). However, the general consensus is that the benefits of NO 
in modulating vasodilation outweigh any potential detrimental effects (Heusche 
et al., 2000, Zhao et al., 2000, Gourine et al., 2001).  
Liberation of NO is facilitated by the activity of endothelial nitric oxide 
synthase enzyme (eNOS) described earlier (Section 1.2.2). eNOs activity is 
stimulated by extracellular signals such as shear stress, acetylcholine, or leukocyte 
adhesion. These stimuli either increase eNOS sensitivity to Ca2+ or increase 
intracellular Ca2+, thus allowing for calmodulin to bind to two eNOS monomers, 
forming a dimer (Föstermann and Sessa, 2012).  Upon dimerization, eNOS is able 
to catalyze the oxidation of L-arginine to L-citrulline, liberating NO from the 
guanidinium group of arginine (Rychter et al. 2016). NO then moves to the 
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vascular smooth muscle cells where it binds with soluble guanylate cyclase, which 
converts guanosine triphosphate to guanosine-3,5’-monophosphate, which drives 
the phosphorylation of downstream proteins signaling overall relaxation of the 
vascular smooth muscle. (Rychter et al. 2016). Thus, NO is a potent vasodilatory 
molecule and this mechanism is central to the finite control of homeostatic 
conditions. 
With the knowledge of NO protection against ischemic attacks it has been 
suggested that clinical administration of nitrites could be beneficial against 
ischemic attacks; however increased dosage of nitrites may lead to major health 
concerns such as the development of methemoglobinaemia and emphysema in at 
risk groups (Mesinga et al., 2003). To overcome this, agents that increase eNOS 
activity (Papapetropoulous et al., 2004, Okayasu et al., 2008) or nitric oxide donors 
(Wang et al., 2002) have been recommended.   
1.5. Dairy Consumption and Cardiovascular Disease 
Dairy consumption is recommended in the daily dietary guidelines of many 
developed countries as well in dietary interventions to aid in lowering 
cardiovascular disease (CVD) risk (Muñoz et al., 1997). However, there has been 
conflicting evidence regarding the influence of dairy products and the protection 
from developing CVD.  These differing views can be attributed to the varied 
composition of dairy products.  Evidence supporting CVD prevention stems from 
the fact that dairy products are typically rich in vitamins, minerals, and protein 
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which can exert beneficial health effects and therefore decrease the risk of CVD 
(Soedamah-Muthu et al., 2011).  Conversely, dairy products also contain saturated 
fat, which can raise low-density lipoproteins and therefore lead to the increased 
likelihood of developing CVD (Soedamah-Muthu et al., 2011).  
In a meta-analysis of cohort studies examining the impact of dairy 
consumption and risk of CVD, it was found that daily consumption reduced the 
risk of CVD by 12% (Qin et al., 2015).  The studies included in this meta-analysis 
included studies that investigated whole milk as well as dairy milk products (such 
as yogurt, cheese, butter and kefir).  The studies differed in regards to which dairy 
products were investigated. It was found that if the cohort studies investigated 
only whole milk products, there was no significant correlation between dairy 
products exhibiting cardioprotection. However, in studies that utilized fermented 
milk products, such as yogurt and kefir, it was observed that there was some 
degree of association in protecting against a CVD (Qin et al., 2015).  It should be 
noted that these milk products can be derived from enzymatic digestion, occurring 
in the gut, or by bacterial fermentation.  Enzymatic digestion is driven by the 
presence of digestive enzymes within the gut, whereas bacterial fermentation is 
due to the proteinase enzymes produced by lactic acid bacteria (LAB); the result 




1.5.1. Cardioprotection by Bioactive Peptides 
During bacterial fermentation, lactic acid bacteria (LAB), such as 
Lactobacillus helveticus, are able to digest large milk proteins, such as α-, β- and k-
caseins, into smaller biologically active peptides and it is these bioactive peptides 
that have come to the forefront of much research (Fitzgerald et al., 2000, Aihara et 
al., 2009, Hirota et al., 2011, Marcone et al., 2015).  Some of these bioactive peptides 
have been highly characterized in regards to their ability to attenuate hypertension 
in vivo (Fitzgerald et al., 2000; Aihara et al., 2015, ), others have been characterized 
based on their ability to regulate the immune system (Marcone et al., 2015), and 
some have also been implicated in influencing vascular tone (Jauhiainen et al., 
2007).  
1.5.1.1. Antihypertensive Properties of Bioactive Milk 
Peptides 
Bioactive peptides have been shown to demonstrate antihypertensive 
properties by acting as an angiotensin converting enzyme (ACE) inhibitor 
(Fitzgerald et al., 2000).  ACE acts as a member of the renin-angiotensin-
aldosterone system (RAAS) which restores homeostatic conditions in response to 
blood volume or pressure decreases as detected by specialized cells of the kidneys. 
More specifically, ACE acts to convert the renin activated angiotensin-I (Ang-1) to 
angiotensin-II (Ang-II); Ang- II then acts as a potent vasoconstrictor to counteract 
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blood pressure drops (Turner and Hooper, 2002).  The use of ACE inhibitors has 
become common in clinical practices to diminish conversion of Ang –I to Ang –II 
to counteract vasoconstriction and thereby aid in lowering blood pressure as a way 
to manage hypertension. By blocking ACE, blood pressure is reduced, thus 
effectively protecting the endothelial layer from sustained elevated levels of shear 
stress.  The ACE inhibitory nature of these bioactive milk peptides has been 
attributed to their amino acid side groups (Fitzgerald et al., 2000); in this review, 
the authors compile a list of previously discovered bioactive peptides and 
demonstrate that bioactive peptides containing proline, lysine, or arginine as the 
C-terminal residue will preferentially bind to and inactivate ACE in order to 
exhibit their antihypertensive effects.  The ACE inhibition potential of the peptides 
used in this study was previously investigated by Adams (2015) who found 
bioactive peptides with C-terminal prolines were able to exhibit greater ACE 
inhibition activity.  
Further to the ACE inhibitory effects of these bioactive peptides, there 
have also been studies demonstrating their NO liberating abilities.  In a study by 
Hirota et al., (2011), two small peptides, valine-proline-proline (VPP) and 
isoleucine-proline-proline (IPP), were able to increase NO production by 50% over 
controls in a HUVEC culture over a 1 hour incubation time. This study also 
investigated the ability of VPP and IPP to induce vessel relaxation by treating 
thoracic aortae isolated from male Wistar rats with varying concentrations of VPP 
25 
 
and IPP ex vivo. It was found that VPP and IPP were able to induce relaxation of 
isolated aortic rings.  
1.5.1.2. Immunomodulatory Effects of Bioactive Milk 
Peptides 
Studies have demonstrated that peptides liberated by LAB fermentation 
can exhibit anti-microbial properties and therefore engage the innate immune 
system.  In a study by Sütas et al., (1996) it was seen that non-specific bioactive 
peptides were able to down-regulate interleukin- 4 (IL-4) production in peripheral 
blood mononuclear cells treated with anti-CD3 antibodies taken from 
hypersensitive, allergic individuals.  More recently, treatment of TNF-α activated 
HUVECs with a casein hydrolysate was shown to downregulate the expression of 
adhesion molecules such as vascular adhesion molecule -1 (VCAM-1), intercellular 
adhesion molecule -1 (ICAM-1) and E-selectin (Marcone et al., 2015).  Suppression 
of adhesion molecule expression by peptides was found to be mediated by 
inhibition of NF-B signaling, decreasing expression levels of these cytokines.  
Bioactive peptides liberated through bacterial fermentation have also 
been implicated in stimulating the proliferation of human lymphocytes and 
increasing phagocytic activities of monocytes (Sütas et al., 1996).  Additional 
studies using high-fat diet (HFD) fed mice showed that administration of VPP 
reduced macrophage infiltration into the adipose tissue (Aihara et al., 2014).  These 
results suggest that VPP can regulate the recruitment of pro-inflammatory cells; 
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however the molecular mechanisms behind these actions are yet to be clarified 
(Aihara et al., 2014).  
1.5.1.3. Bioactive Peptide Effect on Arterial Stiffness 
VPP and IPP have been shown to influence the arterial muscle tone in 
some short term interventions, however, this was found to be attributed to a 
decrease in hypertension or an increase in vasodilatory mediators. In one study by 
Jauhiainen et al., (2007), hypertensive subjects not taking hypertensive medication 
received fermented milk containing VPP and IPP or a placebo.  Ambulatory 
arterial stiffness indices were then obtained for each group and the stiffness index 
was found to improve by 12% in the treatment group and by 5% in the placebo 
group.  This change in muscle tone is proposed to be multifactorial, where the 
muscle tone may be mediated by the overall lowering of systolic and diastolic 
blood pressure.  This change could also be attributed to the increased Ca2+ present 
within the ferments, which aids in vasorelaxation since Ca2+ has been shown to be 





1.6. Development of Physiologically Relevant Models to Study 
the Endothelium  
In typical cell culture investigations, cultures are grown on glass or plastic 
surfaces.  However, in vivo, most cells adhere to much softer substrates, such as 
other cells, a basement membrane or some other extracellular matrix (Yeung et al., 
2005).  Cell functions can depend on the stiffness of the substrate, where stiffness 
represents the circumferential stretch that would be experienced by endothelial 
cells in vivo. The impact of stiffness on cellular functions is likely mediated through 
the cytoskeleton or plasma membrane, causing transcriptional changes and 
changes in chemical signaling regarding cell survival, proliferation, and 
movement (Lo et al., 2000).  Cell survival, proliferation, and migration are key to 
wound healing and also to other physiological processes that seek to regain and 
maintain tight junctional cell barriers.  Notably, maintaining cell – cell junctions 
that promote an endothelial barrier is critical to slow the pathology of 
atherosclerosis.  
Wang et al., (2000) investigated the growth rates of murine embryo fibroblasts 
(NIH/3T3) on soft substrates made of polyacrylamide gels.  Apoptosis was 
measured by terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End 
Labeling (TUNEL) assay as an in situ cell death detection measure.  They found 
that cultures grown on flexible substrates were able to propagate, but cells grown 
on the stiffer substrates showed decreased DNA synthesis and increased 
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apoptosis. This study initially demonstrated that polyacrylamide substrates 
would be a viable option for culturing cells, and may offer a more physiologically 
relevant level of resistance as a surface for in vitro investigations.  
Yeh et al., (2012) further investigated proliferation rates of endothelial cells. In 
this study, endothelial cells were grown on soft substrates as well as stiffened 
substrates as determined by the composition of the polyacrylamide.  It was found 
that cells grown on stiffened gels proliferated at higher rates than cells cultured on 
softer gels. This difference was attributed to the activation of 
integrins/Src/Vav2/RhoA pathway which controls the reorganization of the 
cytoskeleton of the cell in relation to the actin network.  While the culture on softer 
gels demonstrated inhibition of the Src/Vav2/RhoA pathway, stiffer gels 
supported more cell proliferation. This study demonstrated that crosstalk within 
the microenvironment of the vasculature could aid in actin redistribution 
permitting increased cell proliferation within cultures grown on stiffened gel 
matrices (Yeh et al., 2012).  In addition to these growth studies, cultures grown on 
substrate matrices have been investigated in relation to fluid shear stress.  Kohn et 
al., (2015) demonstrated that endothelial cells grown on softer gel matrices became 
more elongated when placed under shear stress.   
The use of polyacrylamide gels was also employed by Huynh et al., (2011) to 
investigate the crosstalk between the endothelium and the extracellular matrix as 
well as leukocyte transmigration.  In this study, BAECs and HUVECs were grown 
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on polyacrylamide gels of increasing stiffness and cells were stained for cadherin 
(as a gap junction protein) and actin for cellular imaging.  It was found that 
intercellular distance differed significantly depending on the matrix on which the 
culture was grown, with high stiffness demonstrating the largest separation width 
between cells as measured by gap junction separation distance. RhoA activation 
was also investigated through a GTPase activation assay (G-LISA).  It was 
postulated that RhoA is activated due to the increased mechanical stress of the 
ECM which would then stimulate RhoA kinase (ROCK) to increase cellular 
contractility by varying actomyosin contraction and cell matrix adhesion, 
therefore leading to increased gap junction distances between cells. The cultures 
were found to exhibit increasing amounts of RhoA with increasing gel stiffness 
that could be inhibited with a ROCK agonist. The cells were then co-cultured with 
neutrophils to investigate paracellular transmigration and shown that cultures 
with high RhoA and ROCK activity had increased leukocyte transmigration 
compared to those cultures treated with a ROCK inhibitor (Huynh et al., 2011).  
The collective studies conducted by Wang et al., (2000), Huynh et al., (2011), 
Yeh et al., (2012), and Kohn et al., (2015), demonstrate that the use of softer 
extracellular matrices to mimic in vivo environments is a viable replacement to 
traditional culture dishes. Although these studies provide information concerning 
cellular morphology and proliferation, effects of changes in extracellular matrices 
on immune-related cell activity is relatively unknown.  
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As described above, a hardened extracellular matrix brought about by arterial 
stiffening would impact gap junctional properties and endothelial barrier function 
(Huynh et al., 2011, Krishnan et al., 2011), contributing to endothelial dysfunction 
and possibly inducing pro-inflammatory immune activity.  Typically, studies 
involving endothelial cells, this later stage inflammatory response is generated by 
stimulation with TNF-α or lipopolysaccharide (Franchi et al., 2008, Marcone et al., 
2015) as a way to study endothelial response to stress.  However, it can be argued 
that the use of chemical stimulation induces an exaggerated state of inflammation 
that does not simulate relevant states of inflammatory distress in endothelial cells.  
As previously suggested, the use of other matrices on which to grow 
endothelial cells can produce models of varying vascular stiffness and can be made 
through the use of polyacrylamide gels. These levels of stiffness can be related to 
the degree by which human vessels experience age-related intimal stiffening and 
used to study endothelial dysfunction (Huynh et al., 2011, Kohn et al., 2015). By 
varying concentrations of polyacrylamide and bis-acrylamide within a 
polyacrylamide gel, varying levels of stiffness can be generated.  The concentration 
of acrylamide to bis-acrylamide correlates to a stiffness that can be measured in 
kilopascal (kPa) using an atomic force microscope (AFM).  The varying ratios of 
acrylamide and bis-acrylamide have been extensively studied and have been 
demonstrated to follow Young’s Modulus (Fischer et al., 2012, Yeh et al., 2012).  
Young’s Modulus is the theoretical measure of stiffness in accordance with the 
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pressure change per square centimeter (O’Rourke et al., 2002) and increasing 
matrix stiffness from 2.5 to 10 kPa is predicted to mimic the age-related stiffening 
of the ECM in humans.  Such a model should, therefore, mimic a range of arterial 
states from healthy to slightly diseased and even severely diseased arteries to be 
used in studies of endothelial dysfunction (Kohn et al., 2015).  The stiffened matrix 
will simulate the stiffened ECM in the vasculature and endothelial cells grown on 
such a range of substrate stiffness might begin to show characteristics of distress 
that characterize a response to endothelial dysfunction, including cytokine release.   
1.7. Objectives 
1.7.1. Characterization of Nitric Oxide Liberation by Bioactive 
Peptides in an Endothelial Cell Culture Model 
Previous studies have linked consumption of fermented dairy products to 
a decrease in the risk factors of cardiovascular disease (Soedamah-Muthu et al., 
2011; Sonestedt et al., 2011).  Additionally, two small bioactive peptides (VPP and 
IPP) have demonstrated the ability to liberate nitric oxide in a HUVEC culture 
(Hirota et al., 2011).  The first objective was to further characterize the bioactivity 
of twelve antihypertensive peptides by comparing the relative the nitric oxide 




1.7.2. Characterization of Behavioural Response of HUVECs to Growth 
on Stiffened Extracellular Matrices 
Evidence to further support and define endothelial cell culture models that use 
gel extracellular matrices as more physiologically relevant is needed (Wang et al., 
2000, Yeh et al., 2012 and Kohn et al., 2015).  Therefore, the second objective of this 
study was to more fully characterize the morphological appearance, growth 





2.1. Cell Culture 
The HUVEC cell line was obtained from Thermofisher (MA, USA) and was 
maintained in MCDB-131 media supplemented in accordance with the findings of 
Terramani et al. (2000). Briefly, basal media was supplemented with 20% fetal calf 
serum (FCS), 1mg/mL epidermal growth factor (EGF), 50μg/mL hydrocortisone, 
10000 units/mL penicillin, 10mg/mL streptomycin, 50μg/mL heparin (all Sigma-
Aldrich, MO, USA), 50μg/mL Endothelial Cell Growth Supplement (ECGS) 
(Corning, NY, USA) and 10mM L-Glutamine (Lonza Group, Switzerland). HUVEC 
growth medium was changed every three days. Cells were grown on collagen 
coated 25cm2 culture flasks at 37oC, 5% CO2 in a humidified incubator 
(Thermofisher, MA, USA). To collagen coat, each flask, rat tail type II collagen 
(EMD Millepore, MA, USA) was diluted to 10ug/cm2 in 0.02M acetic acid and 
1.5mL/25cm2 of this solution was then added to each culture flask. The collagen 
was allowed to adhere to the culture flasks for a minimum of 1 hour under UV 
light in a biosafety cabinet. The flasks were then washed three times with PBS. As 
the final wash, 2mL/25cm2, PBS was added to the culture flask and placed under 
UV light in a biosafety cabinet for a minimum of 1 hour to allow for sterilization 
(Adapted from Sitterley, 2008). Cells were passaged at approximately 80% 
confluency by first aspirating spent media and washing once with room 
temperature PBS before adding 3mL of trypsin-EDTA (Sigma- Aldrich, MO, USA) 
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into the flask. Trypsin was allowed to wash over the monolayer momentarily, 
1.5mL was then removed, and the culture flasks were returned to the incubator for 
2 minutes to detach cells. Trypsin was then neutralized by the addition of 5mL of 
HUVEC cell culture media to the flask. Cells were collected and centrifuged at    
220 x g for 5 minutes. Follow centrifugation, the supernatant was removed and the 
pelleted cell culture was resuspended in 1mL of HUVEC culture media. A trypan 
blue exclusion assay was performed to ascertain cell count and cells were seeded 
at assay specific concentrations.  
HUVEC cells are a primary cell line obtained from a pooled population of 
umbilical veins harvested 14 days or less from a newborn (ThermoFisher, MA, 
USA).  The doubling of HUVEC cultures grown on collagen coated flasks is 
approximately 48 hours (Terramani et al. 2000), with a limited number of 
doublings once cells are defrosted and plated.  All experiments were done on 
passage 2 – 4, which corresponds to the limit of population doublings as 
recommended by ThermoFisher. 
2.2.  Synthesized Peptides 
A list of bioactive peptides that were previously characterized and published 
based on antihypertensive or immunomodulatory activity was obtained from 
Adams et al., 2015 (Table 1). The highly characterized VPP and IPP were 
previously assessed for their ability to liberate NO from cell culture and nine other 
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peptides were chosen for comparison. Synthesized peptides were obtained from 
Bio Basic Inc. (Markham, ON.)  
From these stock solutions, working concentration of 10μmol/L were prepared 




Table 1. Synthesized peptide sequence, molecular weight and reference source of 
β-casein derived peptides from fermentation by Lactobacillus helvicus 
ID# Peptide Sequence MW (g/mol) Reference 
P1 VPP 311.38 
Nakamura et al., 1995 
P2 IPP 325.41 
P3 HQPHQPLPPT 1151.30 
Tellez et al., 2010 
P4 WMHQPHQPLPPT 1468.71 
P5 LYEQPVLGPVR 1270.51 
P6 LDQWLCEK 1034.20 
P7 YP 278.31 Yamamoto et al., 1999 
P8 PGPIPN 593.69 Bourtrou et al., 2013 
P9 FFVAP 579.70 Yamamoto et al., 1997 
P10 KVLPVP 651.85 
Maeno et al., 1996 






2.3. Nitric Oxide Liberation Assay 
Nitric Oxide liberation was assessed by employing a Griess colourimetric 
reaction that measures total nitric oxide; all reagents were prepared as per 
manufacturer’s directions (Enzo Life Sciences, NY, USA). The Griess colourimetric 
reaction is based on the formation of an azo-dye that can be 
spectrophotometrically quantitated; this azo dye is formed by the coupling of N-
(1-naphthyl) ethylenediamine and diazonium salt (Green et al., 1982). The 
diazonium salt is generated by sulfanilic acid reacting with nitrite in solution, 
which is a direct indication of the amount of nitrite, or NO, within the sample. 
For each experiment,  96-well collagen coated culture plates (Corning, NY, 
USA) were seeded with 3500cells/cm2 and allowed to culture and attach for 20 
hours; this was chosen based on initial investigations where NO liberation at 20 
hours was found to be highest compared to 18 hours and 24 hours (data not 
shown). Once the set incubation time had elapsed, the cells were treated for 1 hour 
with 10μmol/L of the peptides in HUVEC medium.  Treatment length of 1 hour 
was chosen based on the research of Hirota et al., (2011), which showed no 
significant difference between treating HUVECs for 1 hour versus 2 hours with 
VPP and IPP. Control wells were treated with fresh HUVEC medium. Upon 
completion of the Griess reaction, the plates were read at 540nm wavelength using 
a Synergy HTTR microplate reader (Bio-Tek Instrumentation, VT, USA).  
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Later investigations took into account the level of arginine in the HUVEC 
medium. Arginine free DMEM medium was used to minimize the level of arginine 
that could act as a substrate to verify that NO being liberated by the HUVECs was 
due to the bioactive peptides. However, the cells were unable to survive for the 1 
hour incubation period. Therefore, this methodology was abandoned and studies 
resorted to the previously outlined protocol.  
2.4. Stiffness Controlled Extracellular Matrix 
Extracellular matrices were manufactured in-house according to the protocol 
outlined by Fischer et al., (2012); a general schematic could be seen in Figure 3.  
Matrix stiffness of 2.5kPa, 3kPa, 10kPa, and 30kPa were chosen. As outlined by 
Galie et al., (2015), 2.5kPa would be below the pressure experienced by the normal 
vasculature; thus acting as a control. Gels exhibiting a stiffness of 3kPa would 
mimic the healthy vasculature, while 10kPa and 30kPa would allow for the 
simulation of the progressively diseased vasculature. 
Coverslips were dried by flaming off ethanol and placed into a Wash-N-Dry™ 
coverslip rack (Sigma-Aldrich, MO, USA). The coverslips were then soaked in a 
0.5% (3-aminopropyl) trimethoxysilane (in ddH2O) for 30 minutes under agitation. 
The slips were then washed in six changes of ddH2O and allowed to dry at 50oC. 
The coverslips were then cooled to room temperature to ensure that a thin, stable 
layer of silane was present on each glass coverslip (Gunda et al., 2014). Once cooled 



















Figure 3. Schematic of polyacrylamide overlaid on top of an activated coverslip, 









minutes under agitation. The coverslips were then washed in three changes of 
ddH2O and allowed to air dry on a bench. By treating the layer of silane with 
glutaraldehyde, a Schiff base functional aldehyde intermediate is formed allowing 
for immobilization of biomolecules (MacMillan, 2009) – in this instance the 
polyacrylamide gel was bound to the coverslip due to this activation. 
Polyacrylamide (PAC) gels were then made with differing volumes of 
acrylamide and bis-acrylamide (Sigma-Aldrich, MO, USA) to simulate differing 
stiffness (Table 2.). The gels were cast on Rain-X treated microscope slides – done 
in order to ensure a hydrophobic surface and therefore allow the gels to adhere to 
the coverslip; 12μL of the PAC gel activated with TEMED and APS was then added 
onto the surface of the slide and the cover slip was gently lowered onto the gel 
allowing for the gel to disperse onto the entire surface of the coverslip. The PAC 
gels were allowed to polymerize for 1 hour, the slides were placed in a petri dish 
and the surface of the slides was flooded with 50mM HEPES, pH 7.5. Using a 
scalpel the coverslips were gently dislodged from the surface of the slide; the 
coverslips were then washed in three changes of 50mM HEPES. 
The coverslips were then placed on an inverted petri dish and covered with 
parafilm. In order to crosslink an extracellular matrix (ECM) suitable for cell 
culture, the PAC gels were treated with sulfo-SANPAH (Sigma-Aldrich, MO, 
USA) under UV light for 8 minutes, after which the coverslips were then washed 
twice in PBS. This treatment with sulfo-SANPAH was done twice to ensure that 
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the PAC gel was sufficiently covered. A 10μg/cm2 solution of rat tail type II 
collagen (EMD Millipore, MA, USA) was then added to the bottom of a parafilm-
covered petri dish and the coverslips were placed on top of the collagen (PAC side 
down). Treatment with sulfo-SANPAH allows for cross-linking through the amine 
reactive group which will adhere to the PAC gel and when placed under UV light, 
the photo-reactive non-specific nitrophenylazide group will be cleaved allowing 
for collagen to attach.  
The coverslips were allowed to crosslink overnight, after which they were 
washed twice with PBS and sterilized under UV. All gels were used within one 




 Table 2. Volume of acrylamide and bis-acrylamide used to produced 1000μL of 
               stiffness controlled PAC gel (Galie et al., 2015) 
Stiffness (kPa) Volume of Acrylamide (μL) Volume of bis-Acrylamide (μL) 
2.5 979 10 
3 976 13 
10 977 12 





2.5. Cell Population Imaging 
HUVECs cultured in 25cm2 culture flasks to 80% confluence cells were lifted 
and seeded onto the stiffness controlled ECM at a cell concentration of 4000 
cells/cm2. Spent media was collected every three days over the course of a nine-
day growth track. After collecting spent media the cells were fixed using a 2% 
paraformaldehyde solution, pH 7.0, for 10 minutes (Sigma-Aldrich, MO, USA), 
after which the coverslips were washed 3Xwith PBS. The fixed cells were then 
stained with safranin (Oxoid, Nepean, ON) for 1 minute and destained using 
ddH2O. The coverslips were then placed PAC gel side down onto a microscope 
slide using ddH2O as a mounting medium. The edges of the coverslips were then 
sealed using clear nail lacquer. The coverslips were then imaged using the 
Panoptiq microscope (ViewsIQ, Richmond, BC) which allows for an image of the 
total growth area to be rendered. The settings for the Panoptiq microscope were 
set to 10x magnification with high scanning capabilities to ensure that images were 
rendered at 1080p.  
2.6. Cell Growth Metrics 
Once total growth images were obtained, total cell number, total cell area on 
each slide and single cellular area measurements were collected using Image J 
software (NIH, MD, USA). Each image was cropped to an area of 13176μm x 
13176μm and toned to gray using the software threshold function (set to ~98%). 
This allows for the image to be split into two classes of pixels, essentially splitting 
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the image into foreground and background. Cells, which would be in the 
foreground would be below 98% and therefore toned to black and objects in the 
background would be above 98%, and would then be toned to white, thus 
allowing for the elimination of background noise while simultaneously enhancing 
cell visibility. Area threshold was set to 10-1000μm2 further allowing for the 
elimination of debris.  Cell counts and area were collected and analyzed for each 
day and matrix stiffness. 
2.7. Cytokine Quantification 
Enzyme-linked immunosorbent assays (ELISAs) were carried out in order to 
quantify Human IL-6 (R&D Systems, Catalogue# DY206), MCP-1 (R&D Systems, 
Catalogue# DY279),  and sICAM-1 (R&D Systems, Catalogue# DY720) from spent 
media collected through each growth track for each matrix stiffness. The capture 
antibodies were coated onto 96-well high-binding Microlon 600 ELISA plates 
(Greiner Bio-One, NC, USA) and allowed to incubate overnight at 4oC. The plates 
were then washed according to R&D Systems specifications and the samples were 
loaded onto the plates and incubated at room temperature for 2 hours. Following 
incubation, the plates were washed and a detection antibody was added for an 
additional 2 hours, after which the plates were again washed and treated with 
horseradish peroxidase (HRP)-conjugated streptavidin for 20 minutes in the dark. 
The plates were washed once again and the substrate to HRP-conjugated 
streptavidin (3,3’,5,5’-tetramethylbenzidine (TMB) (Sigma-Aldrich, MO, USA))  
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was then added to the plates for 20 minutes in the dark. The reaction was stopped 
with 2 N H2SO4 and the plates were gently shaken and read at a wavelength of 
450nm using a Synergy HTTR microplate reader (Bio-Tek Instrumentation, VT, 
USA). 
2.8. Statistical Analysis 
Statistical analysis was done using SPSS (IBM, NY, USA) using a significance 
of p<0.05. For nitric oxide liberation and investigation of cell area, a non-
parametric Mann-Whitney U test was performed. To further define the nitric oxide 
liberating abilities of these bioactive peptides η2 was found for each peptide. This 
was done as described by Coolican (2009). A one-way ANOVA was used to 
analyze cell count, overall cell area and differences in cytokine production, once 
again a Mann-Whitney U test was done to disseminate differences in individual 
cell area between treatments. All data was graphed using Prism by GraphPad 





3.1. Nitric Oxide Liberating Abilities of Bioactive Peptides. 
 The ability of eleven separate peptides (Table 1) to enhance liberation of the 
small signaling molecule NO from HUVEC cells in culture was investigated by 
incubating the cells with a 10μM solution of each peptide for one hour.   Levels of 
NO were measured and recorded using an assay that colourimetrically indicates 
the level of nitrites within the spent media. A Mann-Whitney U-test for 
nonparametric data was used to compare the relative NO concentrations (%) in 
the spent media from each treatment after the incubation time had elapsed. NO 
liberated from HUVEC culture from each bioactive peptide treatment group did 
not differ significantly when compared to the untreated group (Figure 4.). NO 
liberated by the previously uncharacterized peptides WMHQPHQPLPPT, 
LYEQPVLGPVR, LDQWLCEK, YP, PGPIPN, FFVAP, KVLPVP, KVLPVPQ was 
then compared to the NO levels liberated by peptides 2 (VPP) and 3 (IPP), as these 
peptides have previously been reported to increase NO liberation by ~50% in a 
HUVEC culture (Hirota et al., 2011). Once again the relative NO concentrations did 
not differ significantly.  By using the η2 method to calculate the effect size for each 
peptide compared to the untreated group, it was found that, overall, up to 10.5% 
of the NO liberated by the HUVEC cultures could be attributed to the presence of 






























































































































Figure 4. HUVEC were cultured with 10μM of each peptide in MCDB131 enriched 
media for 1 hour (n=6). Data shown are the relative nitric oxide amounts 
produced by each cell culture as a percentage of the untreated. Where 
the horizontal line at 100 represents the average nitric oxide produced 
while untreated. Statistical analysis was performed using Mann-Whitney 




3.2. Characterization of HUVECs Grown on Stiffened PAC 
Matrices – Growth Metrics  
3.2.1. Cell Growth Metrics  
To determine the effects of stiffened matrices on the growth behavior of 
endothelial cells in culture, HUVECs were grown on four different gels that 
simulated stiffness of 2.5kPa, 3kPa, 10kPa, and 30kPa. At 3, 6 and 9 days after the 
initial cell seeding the cultures were fixed, stained and visualized using digital 
microscopy. Sample images can be found in Appendix C.  
3.2.2. Cell Count 
Cell counts taken from each slide using the Image J software were analyzed for 
differences over time and differences between stiffness using a one-way ANOVA.  
Results showed a significant increase only for the day 6 treatment group where 
30kPa cell count was significantly greater than other stiffnesses. (Figure 5). 
Although an overall increase in cell number was generally observed over all 
stiffness treatments, the rate at which each culture grew throughout the 
experiment was observed to be different due to variation in fold change (Table 3.); 
Further to this, it was observed that fold change increased in the softer, more 
compliant matrices of 2.5kPa and 3kPa by a factor of 0.345 and 1.062 respectively; 













































































































2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
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Figure 5. Comparison of cell count between stiffnesses across days; HUVEC cell 
count after 3, 6 and 9 days of incubation on varying PAC gel stiffness; 
with enriched MCBD 131 media at 37oC with 5% CO2 (n=3-4). Cells 
imaged using Panoptiq digital imaging (ViewsIQ, Richmond, BC) and 
counted using Image J (NIH, MD, USA). ‘a’ denotes no statistical 
significance while ‘b’ represents statistically significant cell counts, as 
determined using a one-way ANOVA (p<0.05) and Tukey’s multiple 
comparison tests. Cell counts found at day 6 at stiffness 30kPa was found 
to be statistically higher when compared to cell counts of other stiffness 
at the same time point.  
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Table 3. Fold change in HUVEC cell count between day 3-6 and day 6-9. Cells 
imaged using Panoptiq digital imaging (ViewsIQ, Richmond, BC) and 




Day 3-6 Day 6-9 
2.5 (control) 1.305 1.650 
3 1.040 2.102 
10 1.939 1.524 






compared to days 3 and 6 (Table 3).  Specifically, for 10kPa and 30kPa, the fold 
increase was 1.939 and 2.908, respectively, for days 3-6 compared to 1.524 and 
0.816, respectively, for days 6-9 (Table 3).  
3.2.3. Cell Area 
Cell areas were measured from specimens that fit the limits of threshold 
and particle size specifications in Image J.  Normality tests were initially 
performed to investigate whether the area values were bimodal, perhaps 
indicating two distinct cellular area groups.  It was found that the cell areas were 
positively skewed towards smaller values with the modes being 10.12μm2 for days 
3 and 6 and 2.24μm2 for day 9 for all treatment groups. 
A Mann-Whitney U test of nonparametric data was then performed to further 
define differences in cell areas between the extracellular matrices for each time 
point.  Each treatment (3kPa, 10kPa, and 30kPa) was compared to the area of cells 
grown on 2.5kPa matrices. Using the rank means of each data set, cell areas 
differed significantly from each other at each time point (p<<0.05). Cell areas 
calculated from cells grown on softer gels were greater than those from cells grown 
on the stiffest gels; with the exception of 10kPa matrices (Table 4).  
In order to understand how much total area was taken up on each slide by the 
cells at each stiffness (cell coverage), the average total area occupied by the 
HUVEC culture (n=3-4) was calculated (Figure 6). A one-way ANOVA was done. 
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Table 4. Mean cell area of fixed and stained HUVECs grown on various stiffened 
extracellular matrices. Cells imaged using Panoptiq digital imaging (ViewsIQ, 
Richmond, BC) and counted using Image J (NIH, MD, USA). Statistical Analysis 
was done using a Mann-Whitney-U test (p<0.05) (n=3-4) 
Stiffness Group 
(kPa) 
Mean Cell Area (μm2) 
Day 3 Day 6 Day 9 
2.5 (control) 103.966 ± 138.075 92.133 ± 107.813 108.067 ± 117.213 
3 84.618 ± 119.775  105.266 ± 142.891 92.673 ± 109.992 
10 120.643 ± 139.991 101.906 ± 127.531 117.753 ± 138.362 
















































































































































Figure 6. Comparison of the total area occupied by HUVECs after 3, 6 and 9 days 
of incubation on varying PAC gel stiffness; with enriched MCBD131 
media at 37oC with 5% CO2 (n=3-4). Cells imaged using Panoptiq digital 
imaging (ViewsIQ, Richmond, BC) and measured using Image J (NIH, 
MD, USA). Statistical analysis was done using a non-parametric Mann-
Whitney U test comparing stiffness at a given time point to 2.5kPa 





with Tukey’s Post Hoc analysis for between-group comparisons. Although the 
total area occupied increased with time, there was no difference between groups.  
The fold increase in the area occupied by cells at each stiffness was calculated 
between days 3-6 and 6-9. Although the softer matrices (2.5kPa and 3kPa) were 
found to have a higher fold increase in the total area occupied, the fold increase of 
the stiffer matrix (30kPa) was found to decline with the progression of time, and 
there was no change in fold increase for the 10kPa matrix (Table 5). 
3.3.  Characterization of HUVECs Grown on Stiffened PAC 
Matrices – Release of Cytokines 
To further examine the impact of culturing cells on a stiffened matrix, ELISA   
assays were performed to measure IL-6, MCP-1, and sICAM-1 production.  
3.3.1.  IL-6 
Measured cytokine levels were standardized using the mean cell count for 
each relative stiffness to express the amounts released as relative ng/mL/cell. The 
cytokine levels were then summated to allow for regression analysis using a one-
way ANOVA. It was found that the relative levels of IL-6 production did not differ 
significantly amongst stiffness conditions; however, when levels of IL-6 were 
compared between 3kPa and 30kPa it was found that a trend towards significance 
was observed, where cultures grown on 30kPa gels produced slightly higher levels 
of IL-6. When cytokine levels were compared over time, an increase in IL-6  
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Table 5. Fold change in total area occupied by HUVECs between day 3-6 and day 
6-9. Cells imaged using Panoptiq digital imaging (ViewsIQ, Richmond, 




Day 3-6 Day 6-9 
2.5 1.149 1.953 
3 1.294 1.851 
10 1.638 1.761 




production at all stiffness levels was observed. Comparing IL-6 concentration 
between day 3 and day 6, all groups were found to significantly increase their 
levels of IL-6 production. When comparing day 6 and day 9, significant differences 
were found across all conditions with the exception of 30kPa, where the level of 
IL-6 did not significantly increase (Figure 7).  
3.3.2.  MCP-1 
Measured cytokine levels were standardized using the mean cell count for 
each relative stiffness to express the amounts released as relative ng/mL/cell. The 
cytokine levels were then summated to allow for regression analysis using a one-
way ANOVA. It was found that the relative levels of MCP-1 did not differ 
significantly between stiffness conditions at each time point; however, the levels 
changed between time points for most of the stiffness conditions. Comparing 
MCP-1 concentration between day 3 and day 6, and day 6 and 9, there was a 
significant increase in MCP-1 concentration over time with the exception of the 
30kPa treatment group where the level MCP-1 production did not differ 
significantly from day 3 to 6, or 6 to 9 (Figure 8).  
3.3.3. sICAM-1 
Measured cytokine levels were standardized using the mean cell count for 
each relative stiffness to express the amounts released as relative ng/mL/cell. The 














































































































































Figure 7. IL-6 production by HUVEC culture grown on stiffened extracellular 
matrices for 3, 6 and 9 days (n=5). Data represents standardized IL-6 
production by average cell count for related treatment groups. Statistical 
analysis was done using a one way ANOVA comparing stiffness at a 



















































































































































Figure 8. MCP-1 production by HUVEC culture grown on stiffened extracellular 
matrices for 3, 6 and 9 days (n=5). Data represents standardized MCP-1 
production by average cell count for related treatment groups. . 
Statistical analysis was done using a one way ANOVA comparing 







way ANOVA. It was found that the relative levels of sICAM-1 did not differ 
significantly between stiffness conditions at each time point. Additionally, the 
levels only differed between time points for one of the stiffness conditions. 
Comparing sICAM-1 concentration between day 3 and day 6, and day 6 and 9, a 
significant increase was found only in the 3kPa condition (Figure 9), with other 
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Figure 9. Soluble ICAM-1 production by HUVEC culture grown on stiffened 
extracellular matrices for 3, 6 and 9 days (n=3). Data represents 
standardized sICAM-1 production by average cell count for related 
treatment groups. Statistical analysis was done using a one way 
ANOVA comparing stiffness at a given time point to 2.5kPa (Control) 






4.1. Cell Culture  
A mixed culture of HUVECs was purchased from the supplier (ThermoFisher, 
MA, USA) which represented pooled umbilical vein samples from multiple 
donors, although single donor cell lines are available. Genotyping of HUVEC 
samples by short nucleotide polymorphism (SNP) sequencing has allowed 
researchers to look for polymorphic differences in endothelial cell responses.  For 
example, the NOS3 gene which codes for eNOS has single nucleotide differences 
in exon 7 which changes glutamic acid to aspartic acid (Hingorani et al., 1995). The 
effect of this SNP on NO production has been evaluated and has produced 
controversial results where some have reported lower NO liberation in genotypes 
carrying the SNP (Plantefeve et al., 1999), and others have reported no difference 
in between isoforms (Isabel et al., 2010). Due to the uncertainty surrounding 
atypical results from a single donor, a culture representing a mixed population 
was chosen.  However, it was not determined if the phenotypes in the pooled 
sample include high (Glu/Glu), low (Asp/Asp) or moderate (Glu/Asp) NO 
producers and if the response of the mixed culture was effectively a combination 
of all various responses. Certainly, the response within and between all HUVEC 
cultures in terms of NO production, growth characteristics and viability was 
highly variable, even when culture conditions, media, and plating protocols were 
kept identical.  Variation was also observed between cell sample sources; for 
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example, samples delivered from AllCells (California, U.S.A.) had markedly 
different culture adherence and proliferation characteristics (cell doubling time) 
than HUVECs obtained from ThermoFisher, prompting our repeated purchase of 
only batch number 1391153 for all subsequent experiments in order to maintain as 
much consistency as possible. 
4.2. Nitric Oxide Liberation by Bioactive Peptides 
Bioactive peptides derived from the fermentation of α-casein have shown to 
have a range of action on the endothelium through antihypertensive actions, 
immunomodulatory effects, and NO liberation. Two tripeptides, VPP and IPP, 
have been shown to exhibit significant antihypertensive properties (Aihara et al., 
2005) as well as upregulate the production of NO in culture (Hirota et al., 2011).  
Beyond these two well-known peptides, a short list of nine other peptides was 
compiled (Table 1); these peptides have exhibited anti-hypertensive properties 
(Fitzgerald et al., 2000) including ACE inhibition (Adams, 2015); however, NO 
liberating capacities of these peptides are yet to be fully understood. NO is 
liberated through the action of eNOS through converting the amino acid L -
arginine to L –citrulline (Cockcroft, 2005). NO then diffuses into the smooth muscle 
layer within the vasculature and promotes vasorelaxation. As such, it is important 
to evaluate the nitric oxide liberating capacities of these bioactive peptides in order 
to obtain a thorough understanding of their bioactivity in relation to healthy 
endothelial functioning as well as CVD reduction or prevention.  
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The current study demonstrates that while the bioactive peptides have no 
statistically significant influence on liberating NO from the HUVEC culture, there 
was a wide range of responses by individual cultures (Figure 3). It was also found 
that while some peptides had very little effect, others accounted for up to 10.5% of 
the NO liberated from culture. The remaining NO could be attributed to the 
conversion of L –arginine present within the basal media. Since the basal media 
was estimated to contain 360μM of L –arginine, attempts were made to counter 
this by including a separate NO liberation assay performed on cells starved  of L –
arginine for 1 hour with Dulbecco’s Modified Eagle Medium (DMEM), high 
glucose, no glutamine, no lysine, no arginine (ThermoFisher, MA, USA). The 
media was supplemented to match specifications of the MCDB131 basal media, 
however, serum was omitted due to the increased glucose levels within the DMEM 
media. The cells were unable to survive the one-hour incubation in the absence of 
L–arginine, and serum.  
Looking more closely at the levels of NO liberated (Figure 3), VPP, IPP, and 
KVLPVP are seen to liberate slightly more NO from the culture when compared 
to the other peptides. In our studies, VPP and IPP demonstrated similar NO 
liberating capabilities when compared to the findings of Hirota et al., (2011) where 
these peptides liberated ~50% more NO than basal media control treatment. This 
disparity could be account for by  differences in cell culturing methods; since 
Hirota et al., (2011) used single donor HUVECs it is unclear whether their results 
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are based on low, high or moderate NO producers related to SNPs that may be 
present. Hirota et al., (2011) also allowed cultures to reach confluency prior to 
treating with peptides whereas in the present study cultures were allowed to 
proliferate for up to 24 hours.  These three peptides, interestingly, all contain a C-
terminal proline. The structure of proline is unique in that its side chains are 
cyclized onto the backbone nitrogen atom; when there are multiple prolines in the 
peptide structure a PPII helix is formed (Kay et al., 2000).  This structure allows for 
the residues to be on the same face and interact with proteins. This structure has 
previously been shown to interact with the SH3 domains of the PI3K regulatory 
subunit.  This is interesting to note because eNOs activity and NO production in 
endothelial cells has been shown to be due to the activation of PI3K signaling 
through the insulin dependent pathway (Montagnani et al., 2002). Therefore, it 
could be hypothesized that peptides demonstrating a PPII helix could interact 
with PI3K initiating the pathway leading to increased levels of NO.  Longer culture 
periods in the presence of these peptides would be needed in order to observe 
activation of this signaling pathway resulting in increased eNOs activity.  
A separate mechanism for NO liberation could be employed by peptide 9 
(LYQEPVLGPVR), in that this peptide could act as a nitric oxide donor due to its 
C-terminal arginine. This arginine would donate its guanidinium ring to be 
citrullinated by eNOS and liberate NO. This use of additional arginine has been 
shown to contribute to the synthesis of NO. In a study by Balijepalli et al., (2015) 
65 
 
epithelial cells were cultured with arginine-rich low molecular weight peptides 
derived from protamine. It was found that the peptides were able to generate a 0.2 
fold increase in nitric oxide production over control culture, demonstrating the 
ability of culture to take up additional arginine and employ it in the generation of 
NO.   In our study, excess arginine in the culture media may have obscured 
individual NO generating capacities of the peptides and higher levels of arginine-
rich peptides were not explored. 
4.3. Characterization of HUVECs Grown on Stiffened PAC 
Matrices – Growth Metrics 
Under traditional culture conditions, HUVECs have been demonstrated to 
have a population doubling time of 48 hours (Terramani et al., 2000). However, an 
investigation into how HUVECs behave when grown on substrates of varying 
stiffness are just coming to the forefront of endothelial research (Wang et al., 2000, 
Huynh et al., 2011, Yeh et al., 2012, and Kohn et al., 2015). Therefore, it is important 
to characterize how HUVECs grow and respond over time when grown on these 
extracellular matrices.  
The current study indicates that cell growth was impacted by the stiffness of 
the ECM, with the highest stiffness (30kPa) treatment group on day 6 displaying 
significantly more cells than the lower stiffness groups. In this instance, it was 
found that all other treatment groups were statistically lower in cell count when 
compared to this treatment group (Figure 4).  The results found in the current 
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study support the findings of Yeh et al., (2012) where endothelial cells grown on 
stiffer matrices demonstrated increased levels of proliferation while endothelial 
cells grown on softer matrices exhibited lower proliferation rates.  This difference 
in proliferation rate could be accounted for through mechanical forces sensed by 
integrins within the cell membrane.  Integrins have been demonstrated to form 
unstable bonds with extracellular matrices that normally promote cellular 
attachment. Some of these bonds are strong and long lasting while other are easily 
broken by low mechanical forces (Danen et al., 2002). These force-sensitive 
integrins were investigated by Yeh et al., (2012) for their role in activation of the 
RhoA pathway in endothelial cells grown on increasing PAC stiffness.  They 
proposed that increased cell proliferation was due to activation of the RhoA 
pathway as a result of integrin force sensing detected in cells grown on higher 
stiffness.  In a study by Huang et al., (1998), it was reported that p27 – a cyclin-
dependent kinase (CDK) inhibitor – was upregulated in cells grown on lower 
stress matrices. This increase in p27 was correlated to cell arrest in G1 phase, 
thereby halting mitosis. p27 is phosphorylated and degraded through cyclin 
E/CDK2 which is a downstream signaling molecule of RhoA (Hu et al., 1999). 
Therefore, it is suggested that the increased activation of RhoA in cells grown on 
stiffer matrices allows for the activation of E/CDK2 which actively degrades p27 
and allows cells to progress through the G1/S gateway. 
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In order to look at cell growth rates in our experiments, fold change between 
time-points was compared (Table 3). Interestingly it was found that on softer 
matrices (2.5kPa and 3kPa) fold change was found to increase as time progressed, 
perhaps indicating normal HUVEC population doubling and maintained viability. 
In contrast, there is a decrease in fold change in cultures grown on stiffer matrices.  
This could indicate cell culture decline and slower population doubling over 
extended growth on stiffer matrices (day 6 – 9).  It is proposed that the increase in 
cell number stimulated by the higher stiffness may cause a faster population 
doubling, limiting HUVEC viability and/or induce culture senescence on days 6-
9.  This increase in proliferation is likely due to the external mechanical forces 
exerted on the culture by the stiffness of the gels as reported by Yeh et al. (2012). 
 Mean cell area was also found to differ between treatment groups across the 
days (Table 5), however, the results are varied in terms of response to stiffness. In 
most cases, cellular areas from the 2.5kPa control group were found to be larger 
than the cellular areas of the other treatment groups (3kPa, 10kPa, and 30kPa) 
indicating smaller cell areas with increasing stiffness. Overall it was found that 
cells grown on stiffer matrices exhibited higher cell count with generally smaller 
cells areas.  These two characteristics may be due to the activation of the RhoA 
pathway and the resulting actin redistribution that leads to differences in the 
location of actin stress fibers in cells grown on matrices of varying stiffness.  
Peripheral actin stress fiber distribution is observed in cells grown on softer 
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matrices, while actin stress fibers become distributed more centrally in cells grown 
on stiffer matrices due to RhoA activation (Yeh et al., 2012). The authors of the 
study discuss peripheral distribution of actin on softer matrices as conferring 
isotonic tension in cells, where the cells become distended but tension remains the 
same, while cells were grown on stiffer matrices with higher central actin 
distribution experience isometric tension, where tension across the cell changes 
but the size of the cell remains the same.  Huang et al., (1998) suggest that it is the 
increase in this isometric tension that increases the proliferative abilities of cells.    
Cells grown on stiffer matrices have also been reported to have fewer 
junctional complexes and are less able to withstand force (Krishnan et al., 2011).  
The decrease in cell – cell connections may be another stimulus for cell 
proliferation on higher stiffness matrices.  Under normal conditions, the process 
of contact inhibition halts cell growth, once cells come into contact with each other 
(Kim et al., 2011).  Without contact inhibition on the stiffer matrices, proliferation 
would be greater.  Therefore, the slower growth and larger cell areas of the cells 
grown on softer matrices may more closely resemble cell behavior in vivo.  
Specifically for endothelial cells, these cell-cell connections are crucial to their 
barrier function (Huynh et al., 2011) without which immune cells can begin to 
infiltrate underneath the endothelial cell layer.  With higher cell number and 
smaller cell areas, cells in this study grown on the higher stiffness matrices may be 
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replicating the high cell turnover and increased apoptotic events reported by 
Wang et al., (2000) in their NIH/3T3 cell model of cells grown on stiffer ECM.   
An assay to visualize apoptotic cells in culture on each stiffness would be 
interesting to add to this study. Beyond this, adding staining procedures to 
visualize gap junction and E-cadherins to further understand the cell contact and 
proliferative patterns in HUVECS would be of interest. By furthering this study in 
these directions, additional measures such as the tendency to cluster and 
monolayer formation could be mapped allowing for further investigations into 
HUVEC behavior on stiffened matrices.  
4.4. Characterization of HUVECs Grown on Stiffened PAC 
Matrices – Release of Cytokines 
In the vasculature, the endothelial layer functions to sense mechanical changes 
such as increased blood flow, and cyclical tension. This cyclical tension is 
characterized by the pulsatile movements of the vasculature in tandem with 
systolic heartbeat (Lehoux, and Tegui, 2003).  When changes occur, the endothelial 
layer converts the mechanical stimulus to a chemical signal cascade that 
orchestrates a response (Jufri et al., 2015). When these mechanical stimuli are 
prolonged and amplified, dysfunction within the endothelial layer begins to occur 
with this signaling cascade chronically activated. Typically, investigations of 
atherosclerotic pathways in vitro bypass the initiating mechanical stimulus that led 
to endothelial dysfunction and opt for an inflammatory activation of endothelial 
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cells through the use of TNF-α or LPS (Franchi et al., 2008). When cells are activated 
with TNF-α, NF-B translocates to the nucleus of the cell; this then promotes the 
expression of adhesion molecules – E-selectin, VCAM-1, ICAM-1 – as well as 
cytokines – IL-6 and IL-8 (Modur et al., 1996). However, the concentrations of TNF-
α used in these studies may not always mimic in vivo environments or the 
progressive nature of the dysfunction. In order to obtain a more biologically 
relevant model of the process of endothelial dysfunction in order to study 
inhibition or amelioration of the inflammatory response pathway, the cultures 
should be exposed to the initiating mechanical stimulus, such as, exposing 
endothelial cells to shear stress or culturing on stiffened extracellular matrices. 
These models would allow for the culture to experience a mechanical source of 
stress rather than chemically induced activation. 
Interleukin-6 (IL-6) is produced to signal the immune system to release 
monocytes, and guide them towards areas of distress. IL-6 also decreases 
lipoprotein lipase (LPL) activity and monomeric LPL levels in the plasma. This 
causes macrophages to increase uptake of LDL, thus perpetuating the formation 
of foam cells and increasing the load of the atherosclerotic plaque (Kaplanski et al., 
2003). In a stretch model, Kobayashi et al., (2003), demonstrated that HUVECs 
exposed to progressive stretch will increasingly release IL-6 over time until a 
plateau is achieved; in fact, HUVECs stretched by 150% released a maximum 
amount of IL-6 after 24 hours. In the present study, although it was demonstrated 
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that HUVECs increasingly produced IL-6 over the 9 day incubation time, there 
was no observed difference in IL-6 production between the control and treatment 
groups. This lack of increase could account for IL-6 production reaching its 
maximal expression levels. Since spent media was taken on the third, sixth and 
ninth days, the IL-6 could have reached a plateau. According to Kobayashi et al., 
(2003) after 24 hours there was no change in the amount of IL-6 expressed in 
confluent HUVECs stretched by 125% and 150%.  However, since there was no 
statistical difference in IL-6 levels amongst stiffness treatments, it can also be 
postulated that none of the experimental cells were exhibiting immune related 
activity.  This lack of inflammatory response can be viewed as a positive outcome 
for the characterization of cells grown on stiffness matrices, as they would not be 
classified as undergoing inflammatory distress signaling.  In this way, the model 
may be used to further study endothelial permeability and leukocyte 
transmigration, as investigated by Huynh et al. (2011), or furthered by studies 
concerning oxLDL accumulation, insulin signaling, and eNOS activity. 
Intercellular adhesion molecule- 1 (ICAM-1) is expressed on endothelial cell 
surfaces to allow for leukocyte adhesion. Soluble ICAM-1 (sICAM-1) is the cleaved 
derivative of this adhesion molecule and has been implicated as a measure of 
bound ICAM-1 (Witkowska and Borawska, 2004). Once leukocytes bind to the 
endothelium they transmigrate to the smooth muscle layer; this transmigration is 
assisted through the production of monocyte chemoattractant protein- 1 (MCP-1). 
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MCP-1 is produced byendothelial cells as well as smooth muscle cells; the 
difference in the level of release creates a chemoattractant gradient which allows 
for bound leukocytes to transmigrate the endothelial layer and begin clearing 
foreign bodies; typically oxLDLs (Hansson and Libby, 2006).  
Activation of MCP-1 and sICAM-1 is typically through NF-B signaling, where 
NF-B is upregulated by TNF-α. In a study by Wagner et al., (2009), the 
upregulation of MCP-1 and sICAM-1 in endothelial cells can occur independently 
of TNF-α due to the presence of H2O2 as an activator of NF-B signaling.  Cyclic 
stretch increases the activity of NADPH oxidase (NOX2) which increases the 
formation of O2- which is readily converted to H2O2, this then accumulates in the 
vasculature (Wagner et al., 2009). The accumulation of H2O2 then promotes the 
activation of NF-B which subsequently activates expression of MCP-1 and 
sICAM-1. In the present study, MCP-1 and sICAM-1 production were found to 
steadily increase over the course of time. However, the differences found between 
stiffness groups were found to not be significant (Figure 7 and 8). This lack of 
significance could be attributed to media changes, where levels of H2O2 were not 
allowed to accumulate to a level where NF-B activation would be exaggerated; 
however, levels of NF-B activation were not measured in this study. 
MCP-1 levels and endothelial cell-cell junctions were investigated by Stamatovic 
et al., (2003) who showed increasing MCP-1 levels led to reduced gap junctional 
coupling.  However, MCP-1 was directly delivered to the cells in this model for up 
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to 2 hours. The action of MCP-1 on modulating the cell-cell junctions was found to 
be caused by downstream effects of the RhoA pathway, where ROCK stimulated 
actin-myosin interaction for prolonged periods of time causing increased tension 
across the cell. The increasing levels of MCP-1 seen over the 9 days of culture may 
have influenced the cell – cell junctional behavior of the HUVECs and contributed 
to the decline in proliferation rate seen on the stiffer matrices. 
Overall, this model indicates that there was no significant amount of 
inflammatory signaling induced by the increase in matrix stiffness, perhaps 
indicating that the endothelium does not respond to ECM stiffening with 
inflammatory cytokine release.  This is an unexpected finding due to the reported 
decline in cell-cell junctional connections (Huynh et al., 2011), as well as the 
reported NF-B activation that occurs in cultures stretched on PAC matrices 
(Kobayashi et al., 2003).  It does not appear from our data that the high stiffness 
gels used in this experiment were sufficient to cause endothelial cell distress as 
determined by measuring the production of cytokines IL-6, MCP-1, and sICAM-1, 
although detection of NF-B activation levels at each stiffness was not measured 
as an indicator of inflammatory signaling.    
Tumor necrosis factor alpha (TNF-α) and monocyte colony stimulating factor 





4.5. Conclusions and Future Directions  
In future investigations into bioactive peptide induced signaling by endothelial 
cells, longer term exposure of cell cultures to proline and arginine-rich peptides 
could be used to investigated PI3K signaling, eNOS expression levels, and NO 
liberation.  Unfortunately, it is doubtful that the one-hour exposure employed in 
this study would reveal these longer term impacts of PI3 kinase signaling on 
endothelial cell function. 
Additionally, the use of proline-rich peptides in combination with arginine-
rich peptides could be used to explore the potential for a combination of 
mechanisms that generate endothelial cell responses. In this way, the peptides 
might employ multiple cardioprotective mechanisms in a synergistic fashion, and 
these investigations would more closely simulate the presence of multiple 
bioactive peptides in milk ferment products.  Previous studies have shown that 
consumption of fermented dairy products is able to regulate many mediators of 
cardiovascular disease. More specifically, studies have shown that ingestion of 
fermented dairy products can lead to a reduction of intimal thickening (Ivey et al., 
2011), can lower hypertension (Aihara et al., 2005), while also acting to reducing 
inflammatory activities of monocytes (Aihara et al., 2009).  
 The use of softer matrix substrates to culture cells would appear from this 
study to encourage and regulate normal HUVEC cell growth.  Due to the limits 
of primary cell culture of HUVECs, the maintained cell growth over 9 days on 
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softer matrices may be advantageous; it may be that growing on these soft 
matrices would reduce population doubling time and extend the culture viability 
of HUVECs.  Additionally, these matrices do not induce an overt inflammatory 
response in the cells, leaving other factors to be investigated as instigators of this 
type of response. 
 More experiments are needed to determine if a stiffened ECM contributes 
to endothelial dysfunction beyond a decrease in cell-cell junctional complexes 
and higher cell turnover as has been reported.  The loss of junctional complexes 
on stiffer ECM disrupts the barrier functionality, leading to infiltration of blood 
components, but it may be only the latter that leads to an inflammatory signaling 
response.  Detection of NF-B signaling levels in cells cultured on high stiffness 
gels would add to our knowledge of how arterial stiffness and endothelial 
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II. APPENDIX B 
Structure and properties of bioactive peptides 
 
P1 –VPP 
Molar mass = 311.39 g/mol 
Net charge at pH 7 = 0 
 
P2 – IPP 
Molar mass = 325.4 g/mol 
Net charge at pH 7 = 0 
 
P3 – HQPHQPLPPT 
Molar mass = 1151.27 g/mol 
Net charge at pH 7 = 0.2 
 
P4 – WMHQPHQPLPPT 
Molar mass = 1468.68 g/mol 





P5 – LYEQPVLGPVR 
Molar mass = 269.71 g/mol 





P6 – LDQWLCEK  
Molar mass = 1034.19 g/mol 
Net charge at pH 7 = 3.93 
 
P7 – YP  
Molar mass = 278.3 g/mol 




P8 – PGPIPN 
Molar mass = 593.67 g/mol 
Net charge at pH 7 = 0 
 
P9 – FFVAP 
Molar mass = 579.69 g/mol 
Net charge at pH 7 = 0 
 
P10 – KVLPVP 
Molar mass = 651.84 




 P11 – KVLPVPQ 
Molar mass = 779.97 g/mol 





III. APPENDIX C 
 
Supplementary Figure 1.  
HUVEC culture grown on collagen coated cover slips 3 days after initial seeding 
(passage=2,3). Fixed with 2% paraformaldehyde and stained with safranin. 
Images obtained using digital microscopy 10x (Panoptiq). Images were then 
loaded into Image J for cell count and area measurements. The image above was 
loaded into ImageScope (Leica Biosystems) and a sample of the image was 





Supplementary Figure 2.  
HUVEC culture grown on collagen coated cover slips 6 days after initial seeding 
(passage=2,3). Fixed with 2% paraformaldehyde and stained with safranin. 
Images obtained using digital microscopy 10x (Panoptiq). Images were then 
loaded into Image J for cell count and area measurements. The image above was 
loaded into ImageScope (Leica Biosystems) and a sample of the image was 






Supplementary Figure 3.  
HUVEC culture grown on collagen coated cover slips 9 days after initial seeding 
(passage=2,3). Fixed with 2% paraformaldehyde and stained with safranin. 
Images obtained using digital microscopy 10x (Panoptiq). Images were then 
loaded into Image J for cell count and area measurements. The image above was 
loaded into ImageScope (Leica Biosystems) and a sample of the image was 




Supplementary Figure 4. 
HUVEC culture grown on 2.5kPa polyacrylamide gel overlaid on cover slips, 3 
days after initial seeding (passage=2,3). Fixed with 2% paraformaldehyde and 
stained with safranin. Images obtained using digital microscopy 10x (Panoptiq). 
Images were then loaded into Image J for cell count and area measurements. The 
image above was loaded into ImageScope (Leica Biosystems) and a sample of the 




Supplementary Figure 5. 
HUVEC culture grown on 2.5kPa polyacrylamide gel overlaid on cover slips, 6 
days after initial seeding (passage=2,3). Fixed with 2% paraformaldehyde and 
stained with safranin. Images obtained using digital microscopy 10x (Panoptiq). 
Images were then loaded into Image J for cell count and area measurements. The 
image above was loaded into ImageScope (Leica Biosystems) and a sample of the 





Supplementary Figure 6. 
HUVEC culture grown on 2.5kPa polyacrylamide gel overlaid on cover slips, 9 
days after initial seeding (passage=2,3). Fixed with 2% paraformaldehyde and 
stained with safranin. Images obtained using digital microscopy 10x (Panoptiq). 
Images were then loaded into Image J for cell count and area measurements. The 
image above was loaded into ImageScope (Leica Biosystems) and a sample of the 






Supplementary Figure 7. 
HUVEC culture grown on 3kPa polyacrylamide gel overlaid on cover slips, 3 days 
after initial seeding (passage=2,3). Fixed with 2% paraformaldehyde and stained 
with safranin. Images obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area measurements. The image 
above was loaded into ImageScope (Leica Biosystems) and a sample of the image 





Supplementary Figure 8. 
HUVEC culture grown on 3kPa polyacrylamide gel overlaid on cover slips, 6 days 
after initial seeding (passage=2,3). Fixed with 2% paraformaldehyde and stained 
with safranin. Images obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area measurements. The image 
above was loaded into ImageScope (Leica Biosystems) and a sample of the image 





Supplementary Figure 9. 
HUVEC culture grown on 3kPa polyacrylamide gel overlaid on cover slips, 9 days 
after initial seeding (passage=2,3). Fixed with 2% paraformaldehyde and stained 
with safranin. Images obtained using digital microscopy 10x (Panoptiq). Images 
were then loaded into Image J for cell count and area measurements. The image 
above was loaded into ImageScope (Leica Biosystems) and a sample of the image 




Supplementary Figure 10. 
HUVEC culture grown on 10kPa polyacrylamide gel overlaid on cover slips, 3 
days after initial seeding (passage=2,3). Fixed with 2% paraformaldehyde and 
stained with safranin. Images obtained using digital microscopy 10x (Panoptiq). 
Images were then loaded into Image J for cell count and area measurements. The 
image above was loaded into ImageScope (Leica Biosystems) and a sample of the 





Supplementary Figure 11. 
HUVEC culture grown on 10kPa polyacrylamide gel overlaid on cover slips, 6 
days after initial seeding (passage=2,3). Fixed with 2% paraformaldehyde and 
stained with safranin. Images obtained using digital microscopy 10x (Panoptiq). 
Images were then loaded into Image J for cell count and area measurements. The 
image above was loaded into ImageScope (Leica Biosystems) and a sample of the 





Supplementary Figure 12. 
HUVEC culture grown on 10kPa polyacrylamide gel overlaid on cover slips, 9 
days after initial seeding (passage=2,3). Fixed with 2% paraformaldehyde and 
stained with safranin. Images obtained using digital microscopy 10x (Panoptiq). 
Images were then loaded into Image J for cell count and area measurements. The 
image above was loaded into ImageScope (Leica Biosystems) and a sample of the 





Supplementary Figure 13. 
HUVEC culture grown on 30kPa polyacrylamide gel overlaid on cover slips, 3 
days after initial seeding (passage=2,3). Fixed with 2% paraformaldehyde and 
stained with safranin. Images obtained using digital microscopy 10x (Panoptiq). 
Images were then loaded into Image J for cell count and area measurements. The 
image above was loaded into ImageScope (Leica Biosystems) and a sample of the 




Supplementary Figure 14. 
HUVEC culture grown on 30kPa polyacrylamide gel overlaid on cover slips, 6 
days after initial seeding (passage=2,3). Fixed with 2% paraformaldehyde and 
stained with safranin. Images obtained using digital microscopy 10x (Panoptiq). 
Images were then loaded into Image J for cell count and area measurements. The 
image above was loaded into ImageScope (Leica Biosystems) and a sample of the 





Supplementary Figure 15. 
HUVEC culture grown on 30kPa polyacrylamide gel overlaid on cover slips, 9 
days after initial seeding (passage=2,3). Fixed with 2% paraformaldehyde and 
stained with safranin. Images obtained using digital microscopy 10x (Panoptiq). 
Images were then loaded into Image J for cell count and area measurements. The 
image above was loaded into ImageScope (Leica Biosystems) and a sample of the 
image was captured at 5x magnification (total magnification 500x).  
 
 
